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Abstract
Adverse drug reactions (ADRs) are responsible for a high number of morbidities
and mortalities worldwide and estimated to be the fourth most important cause of death in
the US and Canada after heart diseases, cancer and stroke. ADRs are either type A
(~80%) which are predictable, related to the drug pharmacology and dose-dependent or
type B (~20%), which are unpredictable, unrelated to the drug pharmacology and have no
clear dose-dependency. Drug hypersensitivity reactions (DHRs) represent the majority of
type-B ADRs, which are rare but potentially fatal and unpredictable. The latter aspect
makes DHRs very difficult to diagnose and necessitate the development of a reliable and
safe in vitro diagnostic test to aid prediction and confirm diagnosis. The currently used
tests are not well characterized and their predictive value is unknown. The aim of this
work was to evaluate the clinical value of the currently used diagnostic tests for DHRs; to
develop a simple, reliable and safe test; and to explore the pathophysiology of DHRs
using different approaches for further understanding of the DHRs pathophysiology which
will allow us to develop new means for prevention prediction and diagnosis.
Methodology used involved performing systematic literature reviews, population
survey on previously tested patients, patient recruitment and laboratory techniques that
include preparation and testing of liver microsomes from human and animal origin, using
hematopoietic cell lines and primary cultures of different blood cell types as a surrogate
model to explore DHRs pathphysiology and test patient susceptibility for DHRs.
Systematic review of available literature revealed that the currently used
diagnostic tools for DHRs lack any characterization or standardization and much more
iii

work is needed to further characterize and improve these tools. We developed a novel
laboratory approach for diagnosis of DHRs that proved to be less cumbersome and
potentially more reliable than other currently used tests. Using different biochemical and
genetic methods, we introduced novel concepts that explain some aspects of the
pathophysiology of DHRs.
The main achievement in this research was the development of a novel diagnostic
test for DHRs, the in vitro platelet toxicity assay (iPTA), which has a great potential as a
clinical tool due to its simple procedure and good reproducibility. We hope that these
features will allow its wider clinical use as oppose to other currently used tests. In
addition, expanding our understanding of the molecular pathophysiology of DHRs using
recent technical advances in genetic analysis and laboratory techniques will have a great
impact on the management of these cases.

Keywords
Adverse drug reaction, drug hypersensitivity, in vitro diagnosis, in vitro platelet toxicity
assay, the lymphocyte toxicity assay.
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Preface
This „integrated articles‟ thesis is based on 6 papers I have published over the last
3 years, all focusing on examination of the predictive value of in vitro tests for drug
hypersensitivity reactions (DHRs). These idiosyncratic reactions are often very severe
and may result in serious morbidity and mortality. Hence, it is critical to create and
validate laboratory methods that can identify vulnerable patient before serious reactions
occur.
After presentation of my hypotheses and objectives, I present two systematic
critical reviews of the currently available in vivo and in vitro methods used for diagnosis
and prediction of DHRs. This is followed by description and validation of a new
laboratory method, the in vitro platelet toxicity assay (iPTA), developed by me during the
tenure of my PhD.
The thesis is concluded by an overall discussion of the state of the art of all
aspects of in vitro testing for DHRs.
Thank you for your participation and interest in my work.
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Chapter 1: Objectives and hypotheses.
1.1.

Objectives:
1) To systematically review the literature on patch testing for diagnosis of
hypersensitivity reactions (DHRs).
2) To systematically review the literature on in vitro testing for diagnosis of DHRs.
3) To characterize the predictive value of the lymphocyte toxicity assay (LTA) for
the diagnosis of DHRs.
4) To develop and validate an in vitro platelet toxicity assay (iPTA) for drug
hypersensitivity syndrome.
5) To distinguish between different mechanisms of carbamazepine (CBZ)-induced
hypersensitivity syndrome using novel tests and biological markers.

1.2.

Hypotheses:
1) The available patch tests are not sufficiently standardized and their sensitivity and
specificity are not adequately determined.
2) The available in vitro tests for hypersensitivity syndrome are not standardized and
reproducible to be used clinically.
3) The predictive value of the LTA for aromatic anticonvulsants and sulfonamidesinduced DHRs allows it is clinical use.
4) The iPTA is more sensitive and predictive than the older LTA.
5) In vitro testing using iPTA and LTA and the use of genetic markers such as the
HLA allow identifying two separate mechanisms of CBZ-induced DHRs.

2

Chapter 2: Patch testing for the diagnosis of anticonvulsant hypersensitivity
syndrome: a systematic review.
This chapter has been published previously:
Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for
the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug
Saf. 2009;32(5):391-408.
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2.1.

Introduction
Adverse drug reactions (ADRs) have been defined as undesirable effects associated

with the therapeutic use of drugs.[1] An ADR is defined by the WHO as noxious and
unintended response to a drug that occurs at a dose normally used in man for prophylaxis,
diagnosis or therapy.[2] ADRs represent a major health problem world-wide with high
rates of morbidity and mortality.[3-6] Lazarou and colleagues[4] have estimated in a metaanalysis that ADRs were responsible for nearly 100 000 deaths in the US in 1994. Despite
the fact that this study has been criticized,[7] it does lend credence to the seriousness of
this problem. Indeed, the authors of this study have estimated that ADRs are ranked
between the fourth and sixth leading cause of death, after heart disease, cancer, stroke,
pulmonary disease and accident, in the US and Canada. It has also been demonstrated
that drug-related injuries occur in at least 7% of hospitalized patients,[4] although accurate
estimation of such cases is difficult due to under-reporting.[8] In addition, ADRs also
represent a serious economic burden on the health care system.[9]
ADRs have been classified into the following two types: type-A reactions which are
usually predictable, dose-dependent and related to the pharmacological action of the
drug; and type-B reactions, which are unpredictable, have a delayed onset and cannot be
explained by the pharmacological action of the drug.[10] Type-B reactions are typically
dose-independent; however, dose-dependence of these type of drug reactions can exist at
higher dose ranges than conventional pharmacological dose-response relationships.[11]
Type-B ADRs or idiosyncratic reactions (IRs) comprise various types of reactions such
as immune-mediated (allergic, immunological reactions), which include drug
hypersensitivity reactions or drug hypersensitivity syndrome (DHS), and non-immune4

mediated (sometimes called metabolic idiosyncrasy).[12] Gell and Coombs[13] classified
immune-mediated reactions into four types: type I reactions (immunoglobulin Emediated); type II reactions (through cytotoxic mechanisms); type III reactions (immune
complex-mediated); and type IV reactions, which involve activation of T cells and are
known as “delayed hypersensitivity”. Type IV reactions have recently been subdivided
according to the heterogeneity of T-cell function into Types IVa, IVb, IVc and IVd.[14, 15]
Although an elegant and mechanism-based classification system, many serious and
probable immune-mediated ADRs do not fit into these established categories.[16] DHS is
thought to belong to type IV, T-cell mediated delayed reactions.[17]
Drug hypersensitivity syndrome is a rare but potentially lethal host-dependent ADR
that occurs in susceptible patients upon exposure to specific agents. It has been estimated
that IRs, of which DHS represents a major component (around 10%), constitute from 3%
to 25% of all ADRs.[18] Because of its unpredictable nature and potential severe
morbidity and mortality, DHS is a major problem for patients, clinicians, drug regulators
and the pharmaceutical industry and often deprives patients of effective therapy.
The nomenclature of this type of drug hypersensitivity reaction has long been a topic
of debate.[19, 20] Dilantin hypersensitivity syndrome, sulfone syndrome, dapsone
hypersensitivity syndrome, allopurinol hypersensitivity syndrome, drug-induced delayed
multiorgan hypersensitivity syndrome (DIDMOHS), anticonvulsant hypersensitivity
syndrome (AHS), drug rash (reaction) with eosinophilia and systemic symptoms
(DRESS) and drug-induced hypersensitivity syndrome (DIHS) have all been suggested as
names and acronyms for this disorder.[20, 21] Although no consensus has emerged thus far,
the last three are the most widely used terms. However, for the purpose of this review, it
5

was felt that AHS is the most relevant term because only reactions related to aromatic
anticonvulsant drugs (ACDs) were reviewed.
The objective of this systematic review was to critically review all the relevant
publications related to the use of the patch test in the diagnosis of AHS. We also aimed at
discussing the technical aspects of this in vivo test that contribute to its performance.
2.1.1.

Anticonvulsant Hypersensitivity Syndrome (AHS)
Aromatic ACDs such as phenytoin, carbamazepine and phenobarbitol as well as

some newer agents, including lamotrigine, oxcarbazepine, felbamate and zonisamide
(figure 1), have been implicated in eliciting a whole repertoire of hypersensitivity
reactions ranging from simple maculopapular skin eruptions to a severe life-threatening
disorder. Upon exposure to an implicated drug, a constellation of symptoms develop
including fever, skin eruption and internal organ dysfunction.[22-33] Implicated drugs
include aromatic anticonvulsants (carbamazepine, phenytoin, phenobarbital, lamotrigine),
sulfonamide antibacterials, dapsone, minocycline, terbinafine, azathioprine and
allopurinol.[34] Although AHS is typically defined by the triad of symptoms (i.e. fever,
skin rash and internal organ involvement), it is quite difficult to associate a typical
clinical picture to this syndrome as AHS can manifest as a wide range of clinical
symptoms. Affected patients may develop fever, a skin eruption (from a mild skin rash to
severe eruptions such as Stevens-Johnson syndrome and toxic epidermal necrolysis), and
internal organ involvement (either asymptomatic or symptomatic).[1, 28, 35] The
multivisceral involvement of this illness may include blood dyscrasias (e.g. eosinophilia,
thrombocytopenia), hepatitis, nephritis, myocarditis, thyroiditis, interstitial pneumonitis
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Fig. 1. Chemical structure of aromatic anticonvulsant drugs.
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and encephalitis. Other clinical features of AHS are facial oedema, tonsillitis, pharyngitis,
mouth and lip ulcers, enlargement of liver and spleen, myopathy and disseminated
intravascular coagulation.[35-39] It has been estimated that the incidence of AHS lies
between 1 in 1000 to 1 in 10 000 among patients chronically treated with phenytoin and
carbamazepine.[40] However, these incidences are believed to be inaccurate as a result of
under-reporting.[41]
The exact molecular mechanisms involved in AHS are not well understood. In
fact, it is thought that multiple mechanisms are involved, sometimes simultaneously, to
produce a single event.[39, 42] Discussing detailed molecular mechanisms underlying AHS
is beyond the scope of this review; nonetheless, some recent comprehensive reviews on
this subject are available.[39, 43, 44] In general, AHS is believed to be immune-mediated in
all cases,[17, 45] and the generation of reactive electrophilic drug metabolites that react
selectively and non-enzymatically at nucleophilic sites on multiple proteins to form
immunogenic drug metabolite-protein adducts is proposed to be the initial mechanistic
step in the cascade of cell-based reactions that results in the clinical symptoms.[33, 46-48] At
least a few of the proteins that are covalently modified by metabolites of drugs causing
AHS are likely to be involved in eliciting the immune response that characterizes these
hypersensitivity reactions.[39, 46, 49]
2.1.2. Diagnosis of AHS
A validated, gold standard in vitro test for diagnosis or prediction of AHS is not yet
available. In fact, the value of all currently used in vivo and in vitro tests is widely
controversial and their sensitivities, specificities and variability are yet to be
9

determined.[50-54] Currently, the diagnosis of AHS is based on clinical expertise that is
comprised of: (i) a thorough clinical history, including detailed medication history; (ii) a
comprehensive physical examination; and (iii) available laboratory data. Misdiagnosis of
AHS is very common because the syndrome resembles other conditions such as
infections, collagen vascular disorders and haematological/oncological conditions.[24, 39]
An in vivo systemic rechallenge (drug provocation testing or controlled re-exposure) is
considered to be the gold standard in AHS diagnosis,[55] although ethically this is highly
contentious, as a rechallenge with the implicated drug may result in severe morbidity or
even death. Presently, there are at least three tests available for diagnosis of AHS, namely
the patch test, the lymphocyte transformation test (LTT) and the lymphocyte toxicity
assay (LTA).[50, 55-58] The use of the patch test for the diagnosis of AHS is reviewed here.
2.2.

Research Methodology
We performed the systematic literature search using the databases PubMed,

EMBASE and MEDLINE from their commencement to the 4th week of August 2008
(figure 2).
2.2.1. Search strategies
The first search (Search strategy I) was carried out using key words
“anticonvulsant” and “antiepileptic” in their singular, plural and truncated forms. These
terms were also mapped to their medical subject headings (MeSH) terms. We also
searched for individual aromatic ACDs including „carbamazepine‟, „phenytoin‟,
„phenobarbital‟, „oxcarbazepine‟, „primidone‟, „lamotrigine‟, „felbamate‟ and
„zonisamide‟ both as key words and as MeSH terms when available and the option
„explode‟ was used. The obtained results were combined using „OR‟.
10

In addition, a second search (search strategy II) was carried out using the key
words „skin test‟, „patch test‟ and „epicutaneous test‟ in their singular, plural and
truncated forms. These terms were also mapped to their MeSH terms when available and
the option „explode‟ was used.
The results of the first and second searches were then combined using „AND‟.
The search results were then limited to original articles that were published in English
language and performed on human subjects. At this point, we retrieved 244 articles from
PubMed, 163 articles from MEDLINE and 184 articles from EMBASE. These
publications were then manually reviewed and the following selection criteria were
applied: (i) original articles; (ii) used patch testing for the purpose of diagnosis of
suspected AHS as a result of one or more aromatic ACD(s); and (iii) contained sufficient
technical data.
Applying our selection criteria, 54 articles from PubMed, 43 articles from
MEDLINE and 42 from EMBASE were found to meet our selection criteria. The search
results from the three databases were then combined and duplicates were removed. The
final number of included articles from the three databases was 55.
2.3.

Patch Tests in the Diagnosis of AHS
Patch testing utilizes the concept that a localized, confined, immune-mediated

reaction to the agent of concern can be reproduced by introducing the agent through the
skin. Briefly, the patch test is performed by applying the drug to the tested (ground
commercially available tablets, liquid forms or pure drug powder) on the skin (usually the
upper back) using different devices that give standard surface area exporure. One widely
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Fig. 2. Flow chart of literature search and retrieval process. 1, Search strategies
„anticonvulsants‟ and „patch test‟ include all relevant medical subject headings and key
words as described in the Research Methodology section; AHS = anticonvulsant
hypersensitivity syndrome.

12
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used device is the Finn chamber. The drug is diluted in suitable media (usually
petrolatum, water or ethanol) and the media alone is used as control. The test is then read
for appearance of local reaction after different time periods (20 minutes to 4 days).[59]
This concept has been proven and extensively used for contact irritants and
systemically administered drugs such as the β-lactam antibacterials.[60, 61] Presently, the
positive predictive value (PPV) and the negative predicative value (NPV) of the patch
test in the diagnosis of AHS remain to be determined and its real value is still
unknown.[50] The percentage of concordance between clinically suspected
hypersensitivity reactions and positivity of patch testing varies considerably because of
lack of test standardization.[42, 45, 62]
2.4. Determinants Affecting Patch Test Results
2.4.1. Epicutaneous Penetration
An important determinant of patch test success is the ability of the tested agent
(drug) to cross the skin (epicutaneous penetration) and come into contact with the
processing cells of the immune system (presumably dendritic cells).[63] This property
depends largely on the physicochemical characteristics of the drug to be tested, its
concentration/formulation and the vehicle in which the drug is dispersed or solubilized.
The physicochemical characteristics of the drug determine its polarity and lipidsolubility, thus affecting the ability of the drug to cross the skin barrier and reach the
target cells.[64] In this regard, either the drug itself or its reactive metabolite can be used,
although many reactive metabolites are not available commercially because of their
instability, and purity of the reactive metabolites tested in this manner is an issue. In
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addition, reactive metabolites may not be able to cross the epithelial barrier as they tend
to be less lipophilic and, in some cases, the reactive metabolite is unknown.
Unfortunately, it is not yet possible to comment on the benefit of using metabolites of
ACDs in patch testing because of the paucity of literature on this subject.[53, 62] There are
also cases where opposing results have been obtained when patch testing a drug and its
main metabolite in the same patient.[62, 65] Surveying the literature, it seems that the
ACDs that are most commonly involved in eliciting AHS are carbamazepine and, to
some degree phenytoin. This may be because of frequency of use of carbamazepine and
phenytoin as opposed to prevalence of AHS, therefore, it is not surprising to find many
more investigators interested in studying the toxicity of these drugs compared with other
ACDs. Another possible reason for choosing to work with carbamazepine is because it is
easier to work with in regard to the frequency of positive results in highly imputable
cases.
Once absorbed, carbamazepine is initially metabolized in the liver (or skin) via
cytochrome P450 (CYP) 3A4 and CYP2C8, into at least 33 different metabolites.[66-69]
One of the main metabolites that is also known to have pharmacological activity is
carbamazepine 10,11 epoxide, which is stable and available commercially for research
purposes. Lee et al.[62] patch tested both carbamazepine and carbamazepine 10, 11
epoxide on 13 patients who had exhibited a skin reaction to carbamazepine manifested as
a maculopapular cutaneous eruption. Seven of the 13 patients gave positive patch tests
with the parent drug but negative results with the metabolite; two reacted only to the
metabolite and 1 patient tested positive to both agents. In the same study, all 39 control
subjects who were taking antiepileptic drugs including carbamazepine gave negative
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patch test results to both carbamazepine and carbamazepine 10,11 epoxide. Although the
PPV of the patch test for carbamazepine in this study was good (61.5%), the low
percentage of positive tests when using carbamazepine 10,11 epoxide (23.0%) is difficult
to explain. The authors interpreted these results to be due to either the low concentration
of carbamazepine 10,11 epoxide used or to efficient metabolism of carbamazepine 10,11
epoxide, for example by epoxide hydrolase, in some of the patients. The latter
explanation is more likely.
The use of a reactive metabolite in patch testing has always been hindered by lack
of knowledge of the role of each metabolite of a drug in eliciting hypersensitivity
reactions and response to the exact testing procedure as well as lack of availability of
most of the suspected metabolites due to their chemical instability. Duhra and Foulds[66]
patch tested carbamazepine and oxcarbazepine as well as some of their metabolites (but
not carbamazepine 10,11 epoxide) in a patient with suspected carbamazepine
hypersensitivity. Only carbamazepine gave positive patch test results and they suggested
that the double-bond between positions 10 and 11 of the azepine ring (figure 1) is critical
for skin reactivity. No other study is available in the published literature using patch
testing with metabolites of ACDs.
2.4.2. Type of Drug Tested
It has been shown that the predictive value of a patch test depends largely on the
type of drug implicated in the ADR.[59] Galindo et al.[70] have investigated 23 different
types of ADR, including generalized rash, fever, arthralgia, lymphadenopathy, palpable
purpura, facial erythema, angio-oedema and erythema multiforme, developed to ACDs
in 15 patients using patch testing. They found the patch test to be most useful for ADRs
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involving carbamazepine (PPV 75%) and phenytoin (PPV 60%), whereas the rate for a
positive test was very low (25%) with phenobarbital and lamotrigine. The good PPV
observed with carbamazepine does not seem to be affected by the vehicle used, i.e.
whether it is liquid (water or ethanol) or semisolid (petrolatum).[30, 71] One explanation for
the good PPV of patch testing with carbamazepine could be its high lipophilicity, which
may facilitate its percutaneous penetration and intracellular movement during patch
testing. Indeed, carbamazepine has very good lipophilic properties and a log Koct value of
2.7, which is near the optimum value of 2.5 for transdermal permeation, although other
parameters can be enhanced through some modifications to the chemical structure of the
compound.[72]
2.4.3. Concentration of Tested Drug
The ideal drug concentration in patch testing of anticonvulsants is critical in
obtaining positive results in affected patients without inducing non-specific local
irritation, which may be falsely interpreted as positive results.[60] The concentration
selected should give negative results in control subjects.[73] Because the exposed surface
area of the skin is standard (e.g. using Finn chambers) the amount of drug used is always
expressed as concentration (weight by volume). In published data, the drug concentration
used with ACDs ranged from 0.0001% to 100% pure substance, but the most commonly
used concentrations were between 1% and 10%. However, 0.1% has been the lowest
reported concentration at which a positive patch test to carbamazepine was observed.[7476]

It has been recommended to use pure drug, whenever available, in order to avoid
false-positive results due to hidden additives in the drug formulations[77],degradation
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products or impurities. In all cases, certain guidelines for the preparation of commercially
available drug formulae for patch testing have been suggested.[59, 73]
2.4.4. Vehicle
Petrolatum has been a preferred medium for patch testing of skin sensitizers
because it gives good occlusion and prevents drug degradation as a result of
hydrolysis.[78] Its use has yielded satisfactory results with patch testing of ACDs,[27, 30, 62,
64, 74-76, 79-86]

although, other liquid solvents, such as water,[87] saline,[79] ethanol,[88]

methanol,[89] acetone[90] and propylene glycol,[91] have also been used. Nonetheless, it
appears that using different vehicles does not alter the results,[71] although some liquid
vehicles evaporate during the test, possibly affecting the concentration at which the drug
is introduced.
In addition, applying control patches of the vehicle at the same time as the drug is
critical because some patients may be sensitive to the vehicle itself especially if it is not
of high purity.[92] The state of the drug in aqueous vehicle or in a semisolid medium, such
as petrolatum, are different since the compound may dissolve in the liquid vehicle but be
dispersed as undissolved crystals in the semisolid medium. Thus, we might expect to
have better delivery of the drug using the liquid vehicle rather than petrolatum. In fact,
using in vitro mounted human skin and chromate preparations as a model, Gammelgaard
et al.[93] demonstrated a better skin permeation of the chemical (potassium dichromate)
with aqueous vehicle. It is also interesting to note that paracetamol (acetaminophen) gave
a positive patch test when using an aqueous vehicle and negative patch test when
petrolatum was used as the vehicle.[27]
2.4.5. Timing
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Another factor that seems to be critical to the final result of patch testing is the
timing of the test in regard to the beginning of the hypersensitivity reaction. Some
authors[94] have recommended performing the patch test within 6 months following the
reaction to avoid false-negative results because it is not known how long drug reactivity
lasts. However, others have recorded positive patch tests 6 months to 2 years after the
reaction.[76, 80, 84, 87, 95, 96] In fact, positive patch test results have been obtained in patients
tested 12 years after the adverse reaction to drugs such as sulfamethoxazole.[97] This may
not be surprising as drug-specific T cells can be detected for decades following an
adverse reaction.[45] It is not known if this phenomenon of long-lasting drug reactivity is
drug-dependent, although the frequency of drug-specific T cells is apparently drugdependent.[97]
On the other hand, Jones and coworkers[80] have reported false-negative patch test
results to carbamazepine when the test was performed during or right after the
hypersensitivity episode. In contrast, others[30] have warned about false-positive patch test
results if the test is performed during the increased reactivity period of the
hypersensitivity reaction and recommend waiting for at least 2 months after the
subsidence of the reaction before performing the test. However, positive patch test results
have been obtained when the test was performed during or right after recovery from the
reaction.[27, 71, 79, 85, 90, 98-100]
In reviewing different studies, it seems obvious that performing patch tests during
the acute phase of the reaction appears to yield low rates of positive results,[88, 100-102] and
the optimal timing for the test in this regard appears to be between 2 and 6 months after
the reaction. No mechanistic explanation is available as to why the reaction is not
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detectable early on; however, some have speculated that transient immune depression
during the reaction produces this refractory period.[102] Others propose that transient
selective recruitment of antigen-specific lymphocytes into target organs may lead to the
low number of such cells in the peripheral blood, and thus low reactivity. [84] However, in
the case reported by Okuyama et al.,[102] other factors may have contributed to the
negative results of the patch tests for carbamazepine hypersensitivity during and
immediately after the reaction, including topical and oral co-administration of steroids
during the illness. This observation is supported by the appearance of slightly positive
LTTs during the early stages of the reaction.
2.4.6. Clinical Picture
The clinical picture of the AHS seems to correlate with patch test results, in that
patients with certain types of clinical manifestations seem to react differently to the test.
This is because the clinical manifestations reflect the underlying and integrated
immunological mechanisms of the „reactions‟, which probably differ in one or more
aspects from patient to patient and from one drug to another in individuals.[101, 103] Some
of these underlying reactions are unlikely to be recognized by patch testing, or may not
involve the immunological mechanisms that the patch test was designed to detect. For
instance, when the patch test was used on patients who developed different types of
cutaneous ADRs, such as exanthemas, fixed drug eruptions or urticaria, more positive
results were observed with exanthema patients than in patients with other types of
cutaneous ADRs.[50]
Similarly, Alanko[71] studied 18 patients with different forms of cutaneous
reactions to carbamazepine. Of these, 15 were confirmed by oral rechallenge. Patients
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with maculopapular exanthematous eruptions, exfoliative erythrodermas or erythema
multiforme were found to give positive patch test results in about 70% of those tested,
whereas those with other types of skin reactions including fixed drug eruptions, urticaria
and other types of exanthema all had negative patch test results. However, Alanko et
al.[104] could demonstrate positive patch test results in patients with fixed drug eruption
only if the test were performed on the site of old lesion and not on unaffected skin.
Similarly, Galindo and coworkers[70] have also suggested a correlation between the
histological features of the hypersensitivity reaction and the predictability of testing such
as patch tests. Puig et al.[75] reported that the clinical type of ADR plays a critical role in
the sensitivity of the patch test, which appears to be maximal for maculopapular or
morbilliform reactions.
Of particular importance, delayed hypersensitivity reactions may take more than
one cutaneous form, even in the same patient.[45, 105] Cutaneous manifestations of
reactions to ACDs come in many different forms,[28] some of which could be of pseudoallergic nature,[106, 107] i.e. they may not be mediated by the usual immune mechanisms.
Those reactions, although they mimic true allergic reactions, are unlikely to be detectable
by the patch test.[52] This may explain the low rate of positive patch test results on AHS
patients reported by some investigators.[50, 53, 81, 86, 100]
2.4.7. Other Factors
Other factors that may affect the outcome of the patch test in general are age, sex
and ethnic origin of the patient. Many parameters of skin function, such as thickness, pH,
blood flow and content of lipid, water and protein, are known to change during
ageing.[108-111] These changes can affect the ability of the applied drug to penetrate the
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skin and elicit its effects. With contact allergy, contradictory literature reports have
appeared regarding the effect of age, sex and ethnic origin on results of the patch test.[109,
112, 113]

However, these factors have not been evaluated directly in patch testing of ACDs,

and further comprehensive work is essential if the contributions of these factors to the
variability in patch test results are to be completely understood (table I).
2.5.

Discussion
Our systematic review reveals that there is a deficiency in large-scale studies

determining the usefulness of patch testing in the diagnosis of AHS. Lammintausta and
Kortekangas-Savolainen[50] performed a retrospective study analysing the result of skin
tests including patch testing performed on 947 patients with suspected cutaneous ADRs
during a 13-year period, of whom 56 patients had been exposed to ACDs. Tested patients
had developed a wide range of cutaneous symptoms including exanthema, urticaria,
angio-oedema, fixed drug eruption, vasculitis, purpura and erythema multiforme.
Unfortunately, the percentage of positive tests among these patients was lower than 20%
and no oral rechallenge was performed to validate the predictive value of the patch test in
such cases.
In another study to investigate the suitability of the patch test or the LTT to detect
carbamazepine allergy, Troost and colleagues[88] tested a number of patients using both
techniques. Correlation between positive results of both tests was rather low (r = 0.39, p
= 0.0022). Among a total of 59 patients displaying adverse effects to carbamazepine, 23
had positive LTTs and only 8 of the 23 LTT-positive patients had a positive patch test
(35%).
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Among the published studies, the PPV of the patch testing seems to depend on the
type of antiepileptic drug under investigation, with the highest values obtained with
carbamazepine and the lowest with phenobarbital. These values range from 20% to 80%;
however, it is difficult to draw a firm conclusion because in most of the cases it is only
the medical history of the patients, which provides any evidence of the drug involved.
Oral rechallenge would help confirm the identity of the suspect drug, but because of the
possible severity of the reaction, a systemic rechallenge is rarely performed.
The PPV of the patch test in the diagnosis of AHS appears to be higher than its NPV.
This trend is expected because there are two types of determinants in achieving a positive
patch test: (i) the technical and toxicokinetic characteristics of the agent prior to its
introduction to the immune cells; and (ii) the readiness of the immune system to
recognize this agent and elicit its distinct reaction. Both of these types of factors appear to
contribute to the success of the drug in eliciting a positive patch test. In fact, some
investigators believe it is quite “astonishing” that the patch test can give a positive
reaction at all.[52] This doubt is especially relevant for drugs in which the mechanism of
hypersensitivity is believed to involve long and complex pathways. Positive patch test
results in AHS can be indicative of patient sensitivity to the drug (high PPV) but negative
ones are not conclusive (low NPV) as false-negative results have been described.[136]
The patch test is capable only of detecting a rather strong inflammatory reaction and this
capability depends on how many inflammatory components are involved in the
hypersensitivity reaction.[52] Therefore, weak or intermediate immune responses are
unlikely to be detected by patch testing. Recent advances in genetic research have
allowed the discovery of associations between genetic polymorphisms in certain genes
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Table I. Summary of data: use of patch testing to investigate anticonvulsant hypersensitivity syndrome

No. of
Druga
controls

Conc.
[w/v]
(% unless
otherwise
indicated)

Vehicle

Timeb

Frequency
of positive Reference
result (%)

1

10

Phenytoin

1, 5

Sal

6 mo

1/1

1

10

0.1–20

Sal

6 mo

0/1

1

10

Carbamazepine
Phenobarbital
(phenobarbitone)

10–20

Sal

6 mo

0/1

[114]

Case series

1

0

Carbamazepine

0.1–10

NA

4 wK

1/1

[115]

Case series

1

0

Phenytoin

1

Wat

DUR

1/1

4

0

Carbamazepine

5

Petr

DUR

3/4 (75)

8

34

Carbamazepine

5–20

Petr

1–120 mo

6/8 (75)

1

34

Phenobarbital

5–20

Petr

1–120 mo

1/1

1

34

Oxcarbazepine

5–20%

Petr

1–120 mo

1/1

1

34

Valproic acid

15–60

Petr

1–120 mo

1/1

1

0

Phenytoin

1, 10

Petr/wat

3 mo

1/1

1

0

Carbamazepine

1, 10

Petr/wat

3 mo

1/1

[30]

Case report

1

0

Carbamazepine

NA

NA

NA

1/1

[117]

Retr. cohort

37

5

Carbamazepine

1–30
g/mL

Petr/sal/eth

2 mo–20 y

7/37 (18.9)

Type of study

Case report

Case series

Case report

No. of
pts

24

[27]

[116]

c

c

Type of study

No. of
pts

No. of
Druga
controls

Conc.
[w/v]
(% unless
otherwise
indicated)

Vehicle

Time

Frequency
of positive Reference
result (%)

b

6

5

Phenytoin

1–30
g/mL

Petr/sal/ eth

2 mo–20 y

2/6 (33.3)

8

5

Oxcarbazepine

1–30
g/mL

Petr/sal/ eth

2 mo–20 y

1/8 (12.5)

5

5

Lamotrigine

1–30
g/mL

Petr/sal/ eth

2 mo–20 y

0/5 (0%)

[50]

Case report

1

3

Phenytoin

50 mg/mL

NA

2 mo

1/1

[118]

Case report

1

10

Carbamazepine

10

Petr

NA

1/1

[83]

Case series

1

10

Phenytoin

12.5

PBS

NA

1/1

1

10

Carbamazepine

20

PBS

NA

1/1

1

10

Oxcarbazepine

12.5

PBS

NA

1/1

[119]

Case series

10

40

Phenytoin

10

Petr/eth

NA

3/10 (30)

[81]

Case report

1

3

Valproic acid

Pure

Pure

3 mo

1/1

[120]

Case report

13

39

Carbamazepine

10

Petr

NA

7/13 (53.8)

13

39

Carbamazepine
10, 11 epoxide

1 g/mL

Eth

NA

3/13 (23)

8

20

Carbamazepine

5

Wat

>2 mo

5/8 (62.5)

5

20

Phenytoin

5

Petr

>2 mo

3/5 (60)

Case series

25

[62]

No. of
Druga
controls

Conc.
[w/v]
(% unless
otherwise
indicated)

Vehicle

Time

Frequency
of positive Reference
result (%)

4

20

Phenobarbital

5

Petr

>2 mo

1/4 (25)

[70]

Case report

1

5

Lamotrigine

10

Petr

DUR

1/1

[98]

Case report

1

0

Carbamazepine

NA

NA

1 wk

0/1

[121]

Cohort study

1

20

Carbamazepine

400 g/mL

PBS

6–8 wk

0/1

[122]

Case report

1

0

Carbamazepine

0.1, 1, 2

Petr

1–2 wk

1/1

[123]

Case report

1

0

Lamotrigine

50

Petr

2d

1/1

[124]

Case report

1

0

Carbamazepine

5

Petr/sal

Aft. Rec.

1/1

[87]

Case report

1

0

Valproic acid

20

Wat

9 mo

1/1

[125]

Case report

1

15

Carbamazepine

1, 5

Petr

5 mo

1/1

[121]

Case series

2

0

Carbamazepine

1, 5

Petr

NA

1/2

[125]

Case report

1

20

Phenytoin

1–20

Petr/wat

2 mo

1/1

[126]

Case series

20

0

Carbamazepine,
phenytoin,
phenobarbital

10

NA

NA

12/20 (60)

[34]

Case series

4

5

Carbamazepine

1, 10

Petr

>1 mo

4/4 (100)

[86]

Case report

1

0

Carbamazepine

0.1–10

Petr/wat

3 mo

0/1

[127]

Case series

11

20

Carbamazepine,
Phenobarbital

1

Petr

3–8 wk

5/11(45.5)

[86]

Type of study

No. of
pts

26

b

Type of study

No. of
pts

No. of
Druga
controls

Conc.
[w/v]
(% unless
otherwise
indicated)

Vehicle

Time

Frequency
of positive Reference
result (%)

b

Case report

1

0

Carbamazepine,
phenytoin,
oxcarbazepine

10

Eth

2 mo

1/1

Case series

61

11

Carbamazepine

10

Eth

DUR

12/61 (20)

59

11

Oxcarbazepine

10

Eth

DUR

8/59 (14)

[88]

Case series

7

40

Carbamazepine

1, 5, 10

Petr

>1 mo

6/7 (85.7)

[75]

Case report

1

10

Phenytoin

1

Petr

NA

1/1

1

10

Carbamazepine

1

Petr

NA

1/1

1

10

Phenobarbital

5

Petr

NA

0/1

1

5

Carbamazepine

2

Petr

Right after

0/1

1

5

Carbamazepine

1

Petr

3 mo

1/1

[102]

Case series

4

12

Carbamazepine

0.1–100

Petr/ace

0, 1.5,4 and 6
y

4/4 (100)

[129]

Case report

1

0

Carbamazepine

0.1–10

Per

4 mo

0/1

[130]

Case report

1

5

Carbamazepine

1 and 5

Meth

NA

1/1

[89]

Case series

5

20

Carbamazepine

1

Petr

3 mo–5 y

4/5 (80%)

[80]

Case series

3

0

Carbamazepine

10

Petr/eth/DM
SO

NA

3/3 (100)

[131]

Case report

27

d

[99]

[128]

Type of study

No. of
pts

No. of
Druga
controls

Conc.
[w/v]
(% unless
otherwise
indicated)

Vehicle

Time

Frequency
of positive Reference
result (%)

b

Case report

1

9

Carbamazepine

10, 20,40

YSP

3y

1/1

[96]

Case series

18

20

Carbamazepine

3, 10

Petr/wat/eth

DUR

9/18 (50)

[71]

Case report

1

0

Carbamazepine

100

Pure

Right after

0/1

[66]

Case report

1

20

Carbamazepine

0.1, 1

Petr

4 wk

1/1

1

0

Carbamazepine

10

Petr

4 wk

0/1

Case report

1

0

Carbamazepine

0.001–5

Petr

NA

1/1

[74]

Case series

25

10

Carbamazepine,
Oxcarbazepine

NA

NA

NA

6/25 (24)

[53]

Case series

6

0

Carbamazepine

0.3–20

Petr/sal

NA

4/6 (67)

2

0

Phenytoin

0.3–20

Petr/sal

NA

1/2 (50)

10

0

Phenobarbital

0.3–20

Petr/sal

NA

4/10 (40)

5

0

Valproic acid

0.3–20

Petr/sal

NA

4/5 (80)

[64]

Case report

1

0

Carbamazepine

1, 10, 100

Ace/petr

DUR

1/1

[90]

Case report

1

0

Carbamazepine

Cr.Tab

Petr/wat

DUR

1/1

Case report

1

0

Carbamazepine

0.0001–0.1

Petr

6 mo

Case series

10

80

Carbamazepine

1, 5, 10

Petr

Case report

1

0

Carbamazepine

1–10

Petr

28

c

[132]

c

[85]

1/1

c

[76]

NA

3/10 (30)

[133]

DUR

0/1

[100]

Type of study

No. of
pts

No. of
Druga
controls

Conc.
[w/v]
(% unless
otherwise
indicated)

Vehicle

Time

Frequency
of positive Reference
result (%)

b

Case series

3

0

Carbamazepine

1–10

Petr

4–7 mo

3/3 (100)

[84]

Case report

1

0

Carbamazepine

Pure, 1

Petr/ace

3 mo

1/1

[134]

Case report

1

0

Phenobarbital

20

Pr. gly

Right after

1/1

[91]

Case series

7

18

Carbamazepine

10, 20, 40

Petr

14 wk–7 y

6/7 (85.7)

[95]

Case report

1

4

Phenytoin

1, 5, 10

NA

5 mo

0/1

1
4
Carbamazepine
1, 5
NA
5 mo
1/1
[135]
* = concentration in μg/ml.
** = time elapsed between the reaction and the test.
*** = Frequency of positive results (Percentage).
§: positivity depends on concentration and/or vehicle used.
¥: The suspected drug causing the reaction as suggested by at least the medical history of the patient(s).
¶: Pt with 10% in petr. was slightly positive at 3 days.
Abbreviations: AC = anticonvulsant, Ace = acetone, AHS = anticonvulsant hypersensitivity syndrome, CBZ = Carbemezepine, CBZ-E
= carbamazepine epoxde, Cr.Tab = crushed tablet, CT = number of control subjects, DPH = Phenytoin, DRG = drug, DUR = during,
Eth = ethanol, LMT = Lamotrigine, M = month, Meth = methanol, Petr = petrolatum, PHB = Phenobarbital, Pr. gly = propylene glycol,
PT = number of patients, Retr. = retrospective, Sal = saline, VA = valproic acid, Wat = water, Wk = week, Y = year, YSP = yellow soft
paraffin.
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(e.g. HLA-B and heat shock protein 70) and the risk of specific types of drug
hypersensitivity reactions.[137-143] However, no genetic marker has yet been identified that
has sufficient predictive value to be used as a screening tool for AHS predisposition in
the general population.[138] A recent alert has been issued by the US FDA recommending
screening all patients with Asian ethnicity for the HLA-B*1502 allele before prescribing
carbamazepine because of the proven genetic association between this allele and a high
risk of developing severe forms of hypersensitivity reactions (SJS/TEN).[144] However,
the Asian population consists of multiple ethnic groups that vary considerably in terms of
genetic composition, including the frequency of the HLA-B*1502 allele. Furthermore, no
link was found between this type of mutation and other non-bullous forms of
carbamazepine-induced hypersensitivity reactions, making genetic screening useless in
predicting patient susceptibility to these reactions.[145] However, it is of interest that
different polymorphic alleles were found to associate with specific forms of
hypersensitivity reaction (maculopapular eruption, multiple organ syndrome, SJS, TEN),
implying varying pathological mechanisms for each reaction. This may partially explain
differences in patch test performance in patients developing different clinical
manifestations of AHS.
2.5.

Conclusion
Patch testing is one of the tools that can be used to diagnose or predict AHS. It is

apparent that patch testing can detect only a small portion of the immunological reactions
that underlie AHS, therefore, other diagnostic methods, such as systemic rechallenge,
LTA and/or LTT, should be utilized to make testing more reliable. However, the benefit
of testing appears to be maximal with certain drugs (i.e. carbamazepine and phenytoin)
30

and for specific clinical manifestations (strong reactions). It should be performed 2–6
months after recovery from the date of the ADR for best results, with adequate vehicle
control. In addition, the test procedure must be standardized in order to evaluate its
performance in the diagnosis of drug-induced hypersensitivity reactions.
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Chapter 3: In vitro testing for the diagnosis of anticonvulsant hypersensitivity
syndrome: A Systematic Review
This chapter has been published previously:
Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. In vitro testing
for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol
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3.1. Introduction
Anticonvulsant hypersensitivity syndrome (AHS), also known as drug
hypersensitivity syndrome (DHS) or drug rash with eosinophilia and systemic symptoms
(DRESS), is a type B “Bizarre” adverse drug reaction (ADR) that develops in susceptible
patient following exposure to certain drugs including aromatic anticonvulsants( figure
1).[1,

2]

Although lacking a defined clinical picture, AHS is typically associated with

development of skin rash, fever and internal organ dysfunction that may include blood
discrasias, hepatitis, nephritis, myocarditis, thyroditis and interstitial pneumonitis and
encephalitis.[3] The pathophysiological mechanisms underlying AHS are not well
understood; however it is believed to be immune mediated in general and involve
generation of nucleophilic reactive metabolites that react covalently with macromolecules
to form immunogenic adducts able to activate the immune system.

[4, 5]

The accurate

incidence of AHS is unknown due to underreporting but it has been estimated to be from
1 in 1000 to 1 in 10,000 in patient newly exposed to aromatic anticonvulsants.

[6]

While

the disorder is rare,it is potentially fatal and represents a clinical dilemma to treating
doctors. Diagnosis of AHS is challenging as a reliable and safe diagnostic test is not
available to confirm causality or identify the culprit drug. A number of in vivo and invitro
tests have been devised and used to aid the diagnosis of AHS.[7, 8] These include skin tests
(patch test, prick test, intradermal test), the lymphocyte transformation test (LTT) and the
lymphocyte toxicity assay (LTA).[9] The use of patch test in the diagnosis of AHS has
been reviewed recently.[10] This systematic review is an attempt to evaluate the utility of
in vitro tests used for the purpose of diagnosis of the T-cell-mediated type IV delayed
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AHS reactions. Other tests used for other types of allergic reactions (e.g. IgE
measurement, radioallergosorbent test, basophil activation test) are not reviewed here.
In vitro diagnostic tests have the advantage over in vivo tests (patch test and
rechallenge) of bearing no potential harm to patients. A number of in vitro diagnostic
tests have been used to aid the diagnosis of delayed-type drug hypersensitivity reactions[7,
8, 11-13]

; however, their true value is yet to be defined. Among these tests are those that

utilize peripheral blood monocytes (PBMCs) as target cells, including the LTT and the
LTA. Unfortunately, these techniques require expensive equipment and sophisticated
laboratories as well as specialized experience with biochemical and molecular methods
so only a few centres are sufficiently equipped to perform them. Hence, these methods,
although successfully employed as research tools, have not been successfully translated
to diagnostic tests.[14, 15] The specific aims of the current systematic review are 4-folds: (i)
to evaluate the use of LTT and LTA in the diagnosis of AHS; (ii) to describe the
advantages and limitations of these tests; (iii) to discuss different technical aspects of
both tests with the scope of possible improvement; and (iv) to identify potential future
work to increase the diagnostic value of these tests. The overall objective of this review is
to identify gaps that must be closed to allow these tests to become validated, mainstream
diagnostic tools.
Leukocytes are present in peripheral blood at densities of 5-7 X 103 cells/mm3; 20
to 50% of these cells are lymphocytes whereas 2 to 10% are monocytes. Lymphocytes
are favoured as a model for investigation of immune-mediated diseases because of their
unique characteristics, which include that (i) they are easily obtained at adequate density;
(ii) they play a key role in the immune system by orchestrating different elements of the
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Fig. 1. Chemical structures of aromatic anticonvulsant drugs.
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immune response and thus representing the state of the immune system in the specific
patient; (iii) they are metabolically active and expressing most of the enzymes that are
required for drug detoxication; and (4) individual genetically-based defects in the
expression or activity of these detoxication enzymes are phenotypically expressed in
lymphocytes.[1]
3.1.1. Isolation of peripheral blood mononuclear cells (PBMCs)
Several methods have been used to isolate lymphocytes from heparinised whole
blood including the gelatine method, passage through glass wool or beads as well as
magnetic separation after cellular ingestion of carbonyl iron

[16]

, However, the most

successful and currently most used method is that developed by Böyem[17]. This method
involves centrifugation of diluted blood samples through a gradient of Ficoll®, a synthetic
high molecular weight polymer of sucrose that is highly branched and has low intrinsic
viscosity. This method permits recovery of 60 ± 20% of lymphocytes from original
blood samples with cell viability greater than 90%. This technique allowed the use of
isolated peripheral blood monocytes (PMBCs) in tests such as the LTT and LTA.
3.1.2. The lymphocyte transformation test (LTT)
The in vitro lymphocyte transformation phenomenon was first described during
the late 1950s. In short, human peripheral leukocytes differentiate in short-term primary
cultures, forming plasts. This effect was later attributed to the presence of a constituent,
phytohemoagglutinin (PHA), of plant extract from red kidney beans (Phaseolus
vulgaris), used to isolate blood peripheral leukocytes.[18] PHA causes erythrocytes to
aggregate and sediment allowing leukocytes to separate from whole blood
preparations.[19,

20]

In a later report, Nowell[21] demonstrated that PHA also initiates
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mitotic activity (transformation) in cultured human leukocytes. To confirm the
assumption that the effect of PHA on isolated peripheral blood leukocytes (PBL) has an
immunological basis, Pearmain et al.[22] exposed PBLs isolated from both tuberculinsensitive and non-sensitive patients to tuberculin in vitro. Only PBLs from tuberculinsensitive patients showed mitotic activity whereas cells from patients not previously
exposed to the antigen showed no mitosis.
One of the first reports of using this test for diagnosis of drug allergy was by
Holland and Mauer who evaluated the effect of diphenylhydantoin (phenytoin; DPH) on
cultured lymphocytes isolated from patients sensitive to the drug and non-sensitive
(control) subjects. In these experiments, PHA, used as a positive control showed nonspecific stimulation of all cells sampled whereas DPH stimulated only the cells from
DPH-sensitive patients.[23] With peripheral lymphocytes isolated from a sulphadiazinesensitive patient, this effect was found to be concentration-dependent.[24] In 1966,
Vischer[25] replaced the lengthy visual counting of mitotic figures from fixed slides with a
faster and less subjective method by measuring radiolabelled thymidine incorporation
into cellular DNA as a reflection of the rate of cell division. During the late 1960s and
early 1970s a great deal of work was done by Schellekens and colleagues to optimize the
in vitro lymphocyte transformation technique.[26-30]
The terms Lymphocyte Transformation Test (LTT), Lymphocyte Stimulation Test
(LST) and Lymphocyte Proliferation Test (LPT) are interchangeably used to describe this
technique. The procedure includes incubation of PMBCs isolated from drughypersensitive patients with the incriminated agent at non-toxic concentrations and
observation of any increase in the rate of cell proliferation measured by [3H]thymidine
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incorporation (figure 2). The increase in cell proliferation is expressed as a ratio between
proliferation of cells incubated with and without the drug (control). This ratio is defined
as the stimulation index (SI) and it is calculated as follows:

Value of [3H]thymidine uptake, count per minute (cpm), in the presence of the drug

SI =

Value of [3H]thymidine uptake (cpm) in the absence of the drug vehicle
(
alone)

Cell cultures from drug-exposed and unexposed non-sensitive individuals are also used to
confirm the specificity of a potential drug effect. The final result of the test depends on
several factors such as the value of background cell proliferation and the type of the drug,
however, an SI of > 3 is always considered indicative of a positive reaction.[31] Other
endpoints for measurement of T-cell activation such as elevation of released cytokines
(using an enzyme-linked immunoabsorbent assay, ELISA) have been proposed and could
be a more sensitive method for detection of T-cell activation than measurement of the
rate of cell proliferation.[31,

32]

A recent technique based on staining of intracellular

proteins with carboxyfluorescein succinimidyl ester (CFSE) has been used successfully to
measure T-cell proliferation in vitro.[33, 34] This fluorescent dye is used to non-specifically
label intracellular proteins. In cell proliferation, the intensity of the fluorescent signal is
progressively decreased as the stained proteins are divided during mitosis. An increase in
number of low fluorescent cells indicates cell proliferation that can be measured by flow
cytometry.[35, 36]
The LTT has been used by some investigators for diagnosis of potential drug
allergy cases for more than 20 years.[37] However, its value in diagnosis and prediction of
AHS remains controversial.
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3.1.3. The lymphocyte toxicity assay (LTA)
Introduced by Spielberg and colleagues[1, 38-41] in the 1980s, the LTA is an in
vitro test which utilizes isolated PBMCs to investigate the pathogenesis of idiosyncratic
drug reactions. The test is based on the hypothesis that idiosyncratic reactions develop as
a result of imbalance between generation of toxic reactive metabolites (metabolic
activation or toxication) and detoxication capacity which leads to accumulation of toxic
metabolites (the “reactive metabolite” hypothesis).[4,

42-44]

In this test, lymphocytes are

used not as immunogenic cells but rather as easy to obtain surrogate target cells.[41] The
procedure for the test entails incubation of PBMCs isolated from the patient with the
culprit drug in the presence of phenobarbital-induced mouse, rat or rabbit liver
microsomal 9,000 x g supernatant fraction (S9), as a source of cytochrome P450 (CYP)
monooxygenase activity).
CYP activity in the rodent (or sometimes human) liver preparation is
hypothesized to oxidize drug to its active (cytotoxic) metabolite(s). Lymphocytes contain
enzymes that are required for drug detoxication including epoxide hydrolases (EHs) and
glutathione S-transferases (GST) and any genetic defect in the function of these enzymes
is phenotypically expressed in these cells.[1] The % of cell death is then determined using
different methods for assessing cell death (e.g., trypan blue exclusion or with a
tetrazolium dye, for example by the MTT method). Cell death is assumed to reflect the
vulnerability of the cells to the toxic effects of the drug which is hypothesized to indicate
the susceptibility of the patient to develop hypersensitivity reactions to the parent drug
and its reactive metabolite(s), presumably via differences in detoxication capacity and
immune processing.
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Fig.2. Steps of the lymphocyte transformation test (LTT). HBSS = Hanks balanced salt
solution; PBMCs = peripheral blood monocytes; PBS = phoaphate buffered saline; RBCs
= red blood cells; RPMI = Roswell Park Memorial Institute medium.
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Aromatic anticonvulsants are excellent examples of metabolically activated
cytotoxicants, metabolized, primarily by hepatic CYP isozymes into reactive electrophilic
arene oxide metabolites.[5] These unstable and highly reactive intermediate metabolites
are readily detoxified by EH and/or GST enzymes usually to non-electrophilic products
(dihydrodiols and S-glutathione conjugates, respectively)[45, 46]
Although the same cell model (isolated PBMCs) is used in both types of assay, LTT
and LTA are completely different approaches to the diagnosis of AHS. Whereas the
former detects the in vivo immunological generation of drug-specific T-lymphocytes used
as a sign of hypersensitivity, the latter detects genetic defects that lead to accumulation of
toxic metabolites which are assumed to be a major factor in the etiology of drug
hypersensitivity in addition to possible differences in cell death. Because the two tests use
the same cell model and have similar nomenclature, it is not uncommon for individuals to
confuse the LTT for LTA or vice versa[47] or to use different nomenclature to describe
these tests.[2, 48, 49]
3.2. Research Methodology
In order to evaluate the clinical usefulness of these tests in diagnosis of AHS, we
performed a systematic literature search using three major biomedical citation databases,
PubMed, EMBASE and MEDLINE without any restriction on date from their
commencement to the fourth week of May 2009
3.2.1. Search strategies
Search strategy I: the search was carried out using the key words “anticonvulsant”
and “antiepileptic” in their singular, plural and truncated forms. These terms were also
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Fig. 3. Steps of the lymphocyte stoxicity assay (LTA). MICs = microsomes; MTT = 3(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoluim; NADPH = nicotinamide adenosine
dinucleotide phosphate; PBMCs = peripheral blood monocytes; PBS = phosphate
buffered saline; RBCs = red blood cells.
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mapped to their medical subject headings (MeSH) terms. We also searched for individual
aromatic anticonvulsant drugs including „carbamazepine‟, „phenytoin‟, „phenobarbital‟,
„oxcarbazepine‟, „primidone‟, „lamotrigine‟, „felbamate‟ and „zonisamide‟ both as key
words and as MeSH terms when available and the option „explode‟ was used. The
obtained results were combined using „or‟.
Search strategy II: In parallel, we used as key words „lymphocyte toxicity assay‟,
„LTA‟, „lymphocyte toxicity test‟, „in vitro lymphocyte toxicity assay‟, „in vitro
lymphocyte toxicity test‟, „lymphocyte transformation test‟, „lymphocyte stimulation
test‟, „lymphocyte proliferation test‟, „LTT‟, „LST‟, „LPT‟, „drug-induced lymphocyte
stimulation test‟ and „DLST‟. These terms were also mapped to their MeSH terms when
available and the option „explode‟ was used.
We then combined the results of both searches (search strategy I and search
strategy II) using „and‟ (figure 4).
Retrieved publications were manually reviewed and the following selection
criteria were applied: (i) original articles are written in English; (ii) study is performed on
human subjects; (iii) LTA or LTT was used to diagnose AHS due to one or more
aromatic anticonvulsant drug(s); and (iv) contains sufficient technical data for scientific
evaluation.
Thirty-one articles from PubMed, 22 articles from MEDLINE and 28 from
EMBASE were found that met our selection criteria. The search results from the three
databases were then combined and duplicates were removed. The final number of
included articles from the three databases was 48 articles. Thirty six articles used LTT
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and 12 used LTA for the diagnosis of AHS (figure 4). Although single case reports were
included in the review, none of these reports were used to calculate any of the tests
epidemiological characteristics.
3.3. Results
3.3.1. The LTT in the Diagnosis of Anticonvulsant Hypersensitivity Syndrome (AHS)
The use of the LTT in diagnosis of hypersensitivity to ACDs dated back to the
early 1960s, but its use was almost always confined to experienced technicians in wellequipped research centres, primarily for the purpose of investigating the mechanism of Tcell-mediated reactions rather than diagnosis of drug allergy[14, 15, 50-53] In addition, due to
its low laboratory-to-laboratory reproducibility[31, 54] and hard-to-interpret results,[31] this
test cannot be described as user friendly and requires a great deal of experience for
interpretation of results. For this reason the test has not been translated into widespread
clinical use. In fact, only a few research groups worldwide use this technique
routinely.[31]
Table (I) summarizes data from original publications where LTT has been used to
investigate hypersensitivity reactions to anticonvulsants. Troost et al.[55] directly
addressed the issue of LTT usefulness in AHS diagnosis They collected data from 65
patients who displayed a wide range of adverse effects of carbamazepine (CBZ). They
compared the performance of the patch test (PT) with the LTT and found that the LTT
had a better positive predictive value than the PT (40% and 20%, respectively). However,
the inclusion criteria for the AHS cases were not well described and medical history was
the only evidence that incriminated the drug. Furthermore, the low positive predictive
value of the PT for CBZ (20%) in this study may indicate that some of the cases included
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Fig. 4. Flow chart of literature search and retrieving process. 1 Search strategies
„anticonvulsants‟ and „LTA and LTT‟ include all relevant medical subject heading and
key words as described in section 2.1. AHS = anticonvulsany hypersensitivity syndrome.
LTA = lymphocyte toxicity assay, LTT = lymphocyte transformation test.
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were not typical CBZ-induced hypersensitivity reactions. This is supported by the fact
that only 23% of the included patients displayed systemic manifestations and that 92% of
them had only some form of mild skin reaction as an adverse event.
In an attempt to determine the sensitivity and specificity of the LTT in diagnosis
of allergy to different drugs,[37] files of 923 patients with possible hypersensitivity
reactions to drugs were studied. These patients were classified based on their medical
history, follow-up and provocation tests into four groups where drug allergies were
“definite,” “probable,” “less probable” or “negative”. One hundred cases were considered
to have a very high probability of drug allergy, of which 78 had a positive LTT. Only 3 of
these 100 cases were attributed to ACDs (2 to CBZ and 1 to DPH). The 2 CBZ cases
exhibited positive LTT tests whereas for the DPH case the LTT was negative. Although
the chemistry of the drug in question appears to play a major role in determining the
usefulness of the LTT, the overall specificity and sensitivity of this test in this study were
found to be in the range of 85% and 76%, respectively. It is not known whether or not
these numbers can be applied to ACDs. However, due to the fact that many different
factors are involved in determining the final result of the LTT test as discussed below,
one cannot generalize these figures to include all types of drugs taken under various
conditions.
Numerous factors have been found to affect the predictive value of the LTT in the
diagnosis of drug hypersensitivity reactions. These factors include: the timing of the test
in relation to the beginning of the reaction; the type of clinical manifestations caused by
the drug; the nature of the suspected drug; and the test procedure itself.
3.3.1.1.

Timing of the test.
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Performing the LTT during the adverse drug reaction may result in the high
incidence of false negative test results due to the high rate of spontaneous T-cell
proliferation that does not respond to any additional in vitro stimulation (refractory
period).[50, 55, 56] Houwerzijl and coworkers[57] demonstrated the relationship between the
timing of the test and its outcome. Sequentially testing a number of patients with
hypersensitivity reactions to CBZ, they showed that this refractory period may extend up
to 11 weeks from the time of the adverse reaction. This effect may be due to impaired Tcell function as the predominant T-cell mitogen, PHA could not stimulate T-cells during
this period[57] In contrast,[58] Zakrzewska and Ivanyi obtained positive results when
performing LTT on 6 of 9 patients within 2 weeks of the beginning of the adverse
reaction. These authors attributed their results to the mild form of the adverse reactions
(skin rash only) in their patients. In such cases, a shorter or no refractory period is
expected due to the moderate degree of activation of T-cells.
Although drug-specific T-cells have been isolated from patients decades after the
time of the reaction,[15] a positive LTT is not guaranteed if the test is performed later than
3-4 years after the reaction.

[31]

After remission from severe hypersensitivity drug

reactions the frequencies of circulating drug-specific T-cells was estimated at 1:250 to
1:5000 (from 1:2000 to 1:10,000 for ACDs) and this rate does not appear to be affected
by time. These frequencies were higher than frequencies of T-cells that recognize a full
antigen such as tetanus toxoid (TT).[15] It is well documented that circulating drugspecific T-cells may last for years or even decades[15, 31, 59] after the insult but the length
of this period may vary considerably for reasons not yet understood.
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In a recent study designed to investigate the effects of timing and type of drug
involved in adverse reactions on the utility of the LTT for diagnosis of drug
hypersensitivity, Kano and colleagues[60] followed 12 patients suffering from different
types of drug-induced hypersensitivity reactions (i.e., macula-papular eruption, MP;
Steven- Jonson syndrome, SJS; and AHS or DRESS). Six patients developed AHS as a
result of taking aromatic ring-containing anticonvulsants (DPH, CBZ and phenobarbital;
PHB). Only one of 6 patients showed a positive LTT when the tests were performed
within one week of the onset of the reaction. However, all 6 patients gave positive LTT
results when tested at a later time (ranging from 5 weeks to 1 year). Interestingly, patients
with MP and SJS showed an opposite pattern where the stimulation indices (SI) levels
decreased with time. In another study of one case of CBZ-induced hypersensitivity that
involved pulmonary symptoms, fever, generalized maculopapular erythmatous skin
eruptions and eosinophilia, the LTT performed during the course of the reaction was
positive (SI = 2.2). However, when the test was repeated 3 months after recovery, a
negative result was obtained.[61]
In contrast, Wu et al.[14] did not find any association between timing of the test
and the strength of the response in a cohort of cases of hypersensitivity to CBZ.
Specifically testing a patient < one month after the reaction resulted in a strongly positive
LTT (SI up to 69.4). In the study, similar results were obtained when testing patients at
84 and 180 months after the event, similar to Beeler‟s results[15] at 4 and 19 months after
the reaction. Houwerzijl et al.[57] showed that maximum SI values are obtained if the test
is performed 10 to 20 weeks after the beginning of the reaction, after which the SI values
start to decline over time.
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It appears that during the course of the adverse reaction drug-specific T-lymphocytes
go through three different stages:
1. A highly reactive stage (very strong response) that shows spontaneous
proliferation during which the cells do not respond to any additional in vitro
stimulation.[31,

60]

This stage appears to last for the first 1-4 weeks after the

adverse event depending on the strength of the initial reaction.[57] Stronger
reactions usually result in longer “refractory periods” than weaker ones.
2. An apparently long stage where drug-specific T-cells can be detected in
peripheral blood and are responsive to an in vitro stimulation (strong response).
This stage starts at the remission of the reaction and may last for years and
sometimes for decades.[31]
3. A final stage, where no drug-specific T-cells can be detected in peripheral blood
(weak response). This does not mean that the patient is desensitized to the drug or
is able to tolerate it. In fact, a severe reaction may develop again once the patient
is exposed to the culprit agent.[15, 31]
The so-called refractory period has been attributed to two mechanisms: 1) the
circulating peripheral T-lymphocytes are at their maximum activation and do not
respond to any further stimulation in the presence of the drug; and 2) drug-specific Tlymphocytes are selectively recruited to the affected target organs leading to a
deficiency of these cells in peripheral blood.[55, 57, 64] It has also been observed that
PBMCs isolated from patients during the hypersensitivity episode are characterized
by a high proliferation rate, presumably related to their recent exposure to the culprit
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drug (in vivo). These activated T-cells cannot be further stimulated by exposure to the
drug or PHA in vitro.
3.3.1.2.

Clinical manifestation of the reactions.

Hypersensitivity reactions to drugs can manifest in a wide range of distinct clinical
symptoms including morbilliforme or bullous exanthema, urticaria, as well as
involvement of other internal organs and including fever, blood cell dyscrasia hepatitis,
nephritis and interstitial lung disease.[67,

83]

Severe forms of AHS include erythema

multiform (EM), SJS and toxic epidermal necrolysis (TEN).[84] Some of these reactions
cannot be listed under any known classification of immune-mediated diseases. T-cellmediated drug allergy can take different forms and utilize a variety of mechanisms
including activation of different clones of T-cells and secretion of different types of
mediators.[85] In some cases such as in patients with drug-induced SJS, the proliferative
response of the drug-specific T-cells was found to be low despite the high level of
secreted cytokines.[15] This can affect the ability of T-cell proliferation tests such as the
LTT to detect low levels of circulating drug-specific T-cells, however, in this particular
context measuring cytokines secretion as a readout system for T-cell activation can be
more sensitive than the conventional LTT.[32]
Neukomm et al.

[67]

did not find any correlation between the strength of the LTT

result (SI) and the type of the adverse drug reaction, but showed positive LTT results for
a wide variety of reactions including IgE-mediated reactions. It is quite unexpected that
an in vitro test such as the LTT can give positive results in all cases where drug-induced
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Table I. Summary of data from original work that used the lymphocyte transformation test (LTT) to investigate
hypersensitivity reactions to aromativ anticonvulsants.
Conc. (%
unless
otherwise
indicated)

Time

carbamazepine

1, 10, 100

5

Phenytoin

1, 10, 100

4

4

carbamazepine

1/50-1/100

1

4

Phenytoin

1/50-1/100

1

4

Phenobarbital

1/50-1/100

Case series

7

11

Phenytoin

50ug/ml

1 mo -4Y

Case report

1

0

Phenytoin

200 µg/ml

2 Wk

Type of study

No. of
patients

No. of
controls

Drug

Case series

2

5

1
Case series

Case series

Case series

Read-out

Frequency
of positive
result (%)

2 M, 14 M

CD69
3
H-T

2/2

2 M, 14 M

CD69
3
H-T

1/1

b

< 1mo
> 1 mo
< 1 mo
> 1 mo
< 1 mo
> 1 mo

3

H-T

3

H-T

3

H-T

CFSE
IFN-γ
3

H-T

0/1

CFSE

1/1

2008 [62]

2007[60]
2007[63]

2006[34]

10-200 µg/ml

1-120 mo

3

H-T

2/8 (25%)

32

Oxcabazepine

10-200 µg/ml

1-120 mo

3

H-T

1/1

1

32

Phenobarbital

10-200 µg/ml

1-120 mo

3

H-T

1/1

12

0

carbamazepine

10-100

1-229 mo

3

H-T

11/12
(92%)

1

0

Oxcabazepine

10-100

23 mo

3

H-T

1/1

2006[14]

1

1

Phenytoin

10, 50 µg/ml

19 mo

1

1

carbamazepine

10 µg/ml

4 mo

H-T
CFSE
3
H-T

1/1
1/1
1/1

2006[15]

32

1

3

Case series

2/4
4/4
0/1
1/1
0/1
1/1
7/7 (100%)
5/7 (71.4%)

Year/
Reference

carbamazepine

8

c

a
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2006[64]

Type of study

No. of
patients

No. of
controls

Drug

a

Conc. (%
unless
otherwise
indicated)

Time

b

Read-out

Frequency
of positive
result (%)

CFSE

1/1

Year/
Reference

1

20

Phenytoin

20%

> 6 Wk Aft.
Rec

3

H-T

1/1

1

20

carbamazepine

12.5%

> 6 Wk Aft.
Rec

3

H-T

1/1

2005[65]

Case report

1

0

carbamazepine

NA

29D

NA

0/1

2003[66]

Cohort Study

4

8

Lamotrigine

1-100 µg/ml

5-10Y

3

H-T

3/4 (75%)

2003[51]

Cohort Study

5

8

carbamazepine

1-100 µg/ml

1-72 mo

3

H-T

5/5 (100%)

2003[53]

Cohort study

2

2

carbamazepine

1-100 µg/ml

N/A

H-T
IL-5

2/2 (100%)

2002[32]

Cohort Study

2

>3

carbamazepine

10 µg/ml

6-8 Wks

3

H-T

2/2 (100%)

2001[67]

Case report

1

0

Zonisamide

3,10 µg/ml

N/A

3

H-T

1/1

2001[68]

Case series

2

2

carbamazepine

1,10,100 µg/ml

4-6 Wks

3

H-T

1/1

2001[50]

Case report

1

0

Phenytoin

0.1-1000 µg/ml

101 D

3

H-T

1/1

2000[69]

Case report

1

0

Phenytoin

N/A

AFT REM

3

H-T

1/1

2000[70]

Case report

1

1

Phenytoin /
Phenobarbital

N/A

3 & 16 D

3

H-T

1/1

2000[71]

Case report

1

2

Lamotrigine

0.1-100

3-4 mo

3

H-T

1/1

d

2000[72]

Case report

1

7

carbamazepine

10

N/A

3

H-T

1/1

1999[73]

Case series

3

68

Conc. (%
unless
otherwise
indicated)

Time

carbamazepine

1, 10, 100

N/A

3

H-T

1/1

0

Phenytoin

1, 10, 100

N/A

3

H-T

0/1

1997[37]

1

1

Lamotrigine

0.1-50 µg/ml

3Wks & 1 mo

3

H-T

1/1

1997[74]

65

21

carbamazepine

5, 10, 15

N/A

3

H-T

26/65
(40%)

64

21

Oxcarbazepine

5, 10, 15

N/A

3

H-T

12/64
(19%)

1996[55]

Case report

1

5

carbamazepine

42, 84, 168 µM

2 Wks

3

H-T

1/1

1996[56]

Case series

1

0

carbamazepine

10, 100

1 mo

3

H-T

1/1

1

0

Phenytoin

10, 100

1 mo

3

H-T

1/1

1

0

carbamazepine

N/A

Aft. Rec

3

H-T

0/1

1

0

10,11-carbamazepine
Epoxide

N/A

Aft. Rec

3

H-T

1/1

1995[76]

Case report

1

6

carbamazepine

100 µg/ml

N/A

3

H-T

0/1?

1994[77]

Case series

1

1

Phenytoin

0.01-10 µg/ml

30 D

3

H-T

1/1

1994[78]

Case report

1

0

carbamazepine

25 µg/ml

N/A

3

H-T

1/1

1993[79]

Case report

1

0

Phenytoin

N/A

2 mo

3

H-T

1/1

1989[80]

Case series

9

41

carbamazepine

1-100

1-104 Wks

14

Type of study

No. of
patients

No. of
controls

Drug

Case series

2

0

1
Case report
Case series

Case report

a
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b

Read-out

C-T

Frequency
of positive
result (%)

9/9 (100%)

Year/
Reference

1995[75]

Conc. (%
unless
otherwise
indicated)

Time

10,11-carbamazepine
Epoxide

1-100

1-104 Wks

14

C-T

1/6 (16.7%)

41

Oxcarbazepine

1-100

1-104 Wks

14

C-T

1/6 (16.7%)

1988[58]

1

8

carbamazepine

3,10,30 µg/ml

8 Wks

3

H-T

1/1

1984[81]

6

10

carbamazepine

3,10,30

13Wk-5Y

3

H-T

6/6 (100%)

1

10

Phenytoin

3,10,30

13Wk-5Y

3

H-T

1/1

1977[57]

Case report

1

0

carbamazepine

25 µg/ml

DUR

3

H-T

1/1

1975[61]

Case series

2

25

carbamazepine

10

2-10 mo

3

H-T

1/2

1971[82]

Case report

1

3

Phenytoin

20

10 mo

3

H-T

1/1

1964[23]

No. of
patients

No. of
controls

Drug

6

41

6
Case report
Case series

Type of study

a

b

Read-out

Frequency
of positive
result (%)

Year/
Reference

[a]: The suspected drug causing the reaction as suggested by at least the medical history.
[b]: Time elapsed between the reaction and the test.
[c]: In this particular study 26.5% of control was positive.
[d]: positive skin patch test
Abbreviations: 3H-T = 3H-Thymidine incorporation assay, AC = anticonvulsant, Ace = acetone, Aft. Rec = after
recovery, AHS = anticonvulsant hypersensitivity syndrome, A.R. = after remission, CFSE = caboxyfluorescein
succinimidyl ester dilution assay, Cr.Tab = crushed tablet, DUR = during, Eth = ethanol, mo = month, Meth =
methanol, Petr = petrolatum, Sal = saline, Wat = water, Wk = week, Y = year.
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reactions are attributed to different agents and mediated by distinct immunological
mechanisms. For instance, haptens and pro-haptens such as β-lactam antibiotics require
processing before they are able to activate T-cells whereas other drugs such as CBZ,
lamotrigine (LMG) and SMX and their metabolites are thought to directly activate T-cell
through other mechanisms.[86-89]
Nevertheless, in most of the clinical syndromes associated with aromatic
anticonvulsant use (e.g., generalized macula-papular exanthema, bullous reactions, multi
organ DRESS syndrome, etc.) the LTT is frequently positive.[31] As mentioned earlier,
severe bullous reactions such as TEN rarely yield a positive LTT, and the reason behind
this is unknown. Romano et al.[64] tested 8 patients with a history of hypersensitivity
reactions to CBZ (6 patients with macula-papular exanthema (ME), one with bullous
exanthema (BE) and one with SJS). All 6 cases with ME yielded negative LTT results
despite a positive patch test in 4 of them. On the other hand, the test was positive with the
other two cases (BE and SJS). Six ME patients were tested within 2 years of the adverse
reaction whereas the BE and SJS cases were tested 6 and 12 years later, respectively.[64]
The LTT detects circulating peripheral drug-specific T-lymphocytes. Such
aromatic anticonvulsant reactive T-cells have been cloned and characterized in multiple
previous studies.[14,

15, 51, 53, 63, 90]

If, for whatever reason, the pathophysiology of the

disease does not involve a high frequency of circulating drug-specific T-cells, the LTT
will not confirm the diagnosis. The mediocre sensitivity of the LTT in the diagnosis of
AHS (around 70%) has provoked uncertainty about the real pathophysiology of this
disorder and whether it actually exists. There is increasing evidence on the heterogeneity
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of AHS reactions and that they might be mediated by distinct yet unidentified
pathophysiology mechanisms.[43, 44, 91, 92]
Recognition of the suspected drug by the isolated peripheral lymphocytes is
another dilemma as antigen processing does not seem to be required for T-cell activation
in vitro. This can be partially explained by a relatively recently introduced paradigm, the
“p-i" concept. This term stands for “direct pharmacological interaction of drugs with
immune receptors” and assumes that a chemically inert drug can non-covalently interact
with receptors on the immune cells and activate them without being a full antigen. [87]
This interaction that involves only T-cells may explain why drugs such as CBZ elicit only
T-cell-mediated adverse effects while haptens (β-lactam antibiotics) are able to cause all
sorts of idiosyncratic reactions including anaphylaxis. In fact, some investigators have
found the LTT to be useless in the diagnosis of reactions such as pneumonia caused by
minocycline, bucillamine, amoxicillin and clindamycine[93-95] or hepatitis due to herbal
medicines.[94] This probably is because these reactions were mediated by other
mechanism(s). However, in cases with multiple organ involvement including liver
dysfunction, the LTT is more likely to yield positive results.[72] This suggests that several
different immunological mechanisms underlie the apparent clinical manifestations.
3.3.1.3.

The specific drug.
The LTT has given positive results with most aromatic anticonvulsant drugs

including DPH, CBZ, oxcarbazepine (OCBZ), PHB, LAM and zonisamide (ZIM) with
sensitivity ranging between 25% and 100%.[14, 53, 55, 63, 68, 96] However, issues related to the
chemistry and pharmacology of the tested drug may limit the outcome of the LTT. One
such problem may be the solubility of the tested drug in the incubation medium. The
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majority of the lipophilic aromatic anticonvulsant are not water soluble and require
solubilisation in an organic solvent (e.g., dimethyl sulfoxide, ethanol or propylene
glycol). It is important to ensure that the final concentration of the solvent in the medium
is not cytotoxic. In addition some researchers found that it is necessary to sonicate the
drug solution to enhance its solubility.[60]
In addition, some drugs may cause non-specific activation or deactivation of
PBMCs resulting in false positive or false negative LTT results. Higher concentrations of
CBZ or DPH cause cytotoxicity and kill PBMCs, an effect that may mask any expansion
of lymphocytes, resulting in low SI levels (false negative). Therefore it is essential to
examine the effects of the used drug concentration on cells stimulated by the non-specific
mitogen PHA.[31]
The effect of coadminstrated systemic corticosteroids on test results is
controversial. Although some researchers state that systemic administration of more that
0.2mg/kg of prednisolone may interfere with the LTT,[31] others have found no such
effect.[60]
3.3.1.4.

Test procedure and read-out system.
The most evident pitfalls of this in vitro diagnostic test are its complicated

procedure and lack of standardization.[31] Attempts to simplify the test procedure and
improve its reproducibility have been described for decades[32, 34, 37, 58, 62] however, the
long-sought simple and reproducible LTT is not yet achievable. The common challenge
among aromatic anticonvulsants is their need to be enzymatically activated to more
reactive metabolites to elicit their presumed HS reactions.[42, 49] This observation has led
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some researchers to use liver microsomes to increase the test sensitivity.[97] Others have
also used ex vivo serum from healthy volunteers taking the drug.[78] However, these
approaches did not improve the sensitivity of the test.
Another important aspect of the LTT is the read-out method. Traditionally T-cell
proliferation is measured by [3H]thymidine uptake which has proven to be very
reproducible. Other methods to detect T-cell activation including such synthesis and
release of IL-5, IL-10, IFN-γ and CD69 have also been used and shown to improve the
sensitivity of the test.[62, 98] Other workers have also used increased secretion of soluble
Fas ligand (sFasL) as a read-out or biomarker and found this protein to be significantly
increased in patients with CBZ-induced blistering diseases (SJS/TEN).[13, 99] Granulysin,
a cytolytic and proinflammatory protein excreted by activated cytotoxic T lymphocytes
(CTLs), natural killer (NK) and NKT cells.

[100]

It was shown to be a key mediator of

keratinocyte apoptosis in severe bullous reactions and to be present in high
concentrations in blister fluids in patients with CBZ- and DPH-induced SJS and TEN.[101]
Expression of such mediators can be of clinical value in diagnosis or determining the
prognosis of drug-induced bullous reactions
3.3.2. Lymphocyte toxicity assay (LTA):
The use of the LTA in diagnosing AHS dates back to the early 1980s.[40]
However, except for 4 major studies,[1, 102-104] the lack of large scale application is quite
obvious. Shear and Spielberg[1] studied 53 patients with a medical history suggesting
AHS due to DPH, CBZ or PHB as well as 49 unexposed healthy controls and 10 DPHexposed healthy controls. Symptoms included fever, skin rash (varied in severity from
generalized exanthema to TEN), eosinophilia, atypical lymphocytosis and internal organ
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involvement (liver, kidney, thyroid or lung). The performance of the LTA as a diagnostic
test in this cohort of patients was excellent, with only 2 false positive and one false
negative results in patients with hypersensitivity reactions to PHB. Naranjo et al.[104]
tested 51 patients with highly likely diagnosis of AHS to DPH, CBZ or PHB and
estimated the sensitivity and specificity of the LTA to be 99% and 75%, respectively.
However, only 8 drug-tolerant patients were included in the study, rendering precise
determination of the specificity of the test impossible. On the other hand, the lack of a
gold standard against which results of the LTA can be validated has always made these
numbers merely an estimate.
In another study by Neuman and colleagues the LTA was used to diagnose AHS
in 86 patients, 62 of them developed an adverse reaction as a result of taking aromatic
anticonvulsants.[102] Although the inclusion criteria for the cases were not well defined,
the sensitivity and specificity of results of the LTA in the diagnosis of AHS were
estimated to be 98% and 89%, respectively and the positive and negative predictive
values were found to be 90% and 64%, respectively. To evaluate cross reactivity among
old aromatic anticonvulsant (DPH, CBZ and PHB) and zonisamide (ZNS), a new
aromatic anticonvulsant, Neuman et al.[103] tested 20 AAC-hypersensitive patients and
20 AAC-tolerant patients using the LTA. Tested patients had exhibited a broad spectrum
of AHS manifestations including fever, skin rash, internal organ involvement, SJS and
TEN). The authors estimated the sensitivity and specificity of LTA in this cohort of
patients to be 92.9% and 99.1, respectively.
In a technician blinded, hospital based controlled study, Dwivedi et al.[105] tested
11 patients with AHS to DPH. Five patients had SJS, 4 had erythrodermic eruption, 1 had
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morbilliform eruption and 1 lichenoid eruption. The authors also tested 11 healthy and
DPH-tolerant volunteers as controls. All 11 patients gave positive LTA (% of cell death
ranged between 7% and 26% as compared to 2.6% and 3.5% for controls). It is of note
that in this study cells from patients with a severe form of AHS (SJS) exhibited a higher
percentage of cell death (12-26%) than milder forms (7-13%) and that was related to a
greater deficiency in expression or effectiveness of detoxifying enzymes.
The LTA is simpler and has a less complicated procedure than the LTT, not
requiring radioactive reagents. However, the sensitivity and specificity of the LTA in
determining the culprit drug in AHS have not been extensively evaluated, mainly due to a
lack of strict inclusion criteria in the reported cases. A systemic rechallenge could be a
definitive proof of drug culpability but this is ethically unacceptable because of the
possibility of danger to the patient.
3.4.2.1. Technical considerations for the LTA
As outlined earlier, the basic principle of the LTA is to generate in tube the presumed
cytotoxic metabolite(s) of the suspected drug in the presence of the surrogate cell model
and to measure lymphocyte susceptibility to metabolite-induced cell death. This process
depends largely on the test procedure and reagents used. Table (3) summarises the
different steps to be considered in optimizing the performance of the LTA.
For example, contamination of isolated PBMCs with platelets can affect lymphocyte
function and activity in vitro [109, 110] and may also modify the evaluation of cell death by
the MTT method. Platelets have unusually high numbers of mitochondria (the source of
the succinate dehydrogenase enzyme that converts MTT to blue formazan dye) and their
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presence in the medium can compromise the signal (unpublished data). A number of
methods have been introduced to prepare platelet-free PBMCs,

[109, 111-114]

although this

increases the cost and complexity of the test. On the other hand, the usage of platelets as
a surrogate model in place of PBMCs could be advantageous as platelets are easier to
isolate and more abundant in peripheral blood than PBMCs. They were found to respond
with the same way as PBMCs to different chemical insult and platelets from drug
hypersensitive patients were found to be more susceptible to cell death induced by the
suspected drug than platelets from healthy volunteers who have never exposed to the
drug (under preparation).
In addition, the in vitro metabolic activation system (liver microsomes) plays an
important role in the success of the test especially when testing drugs such as those
aromatic anticonvulsants whose toxic metabolites are still unknown. Differences among
species in terms of metabolic activation of drugs by CYP isozymes[115] and their relative
levels expression in untreated and induced microsomal systems should be considered
when performing the LTA. The incubation conditions of the surrogate cells with the
suspected drug and liver microsomes should be standardized. The pH of the medium have
a tremendous effect on the viability of PBMCs (unpublished data), therefore, the pH
should be adjusted to 7.2-7.4 just prior to performing the test. Other additives such as
fetal bovine serum (FBS) are also essential to the viability of the cells and should be
standardized.
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Table II. Summary of data from original work that used lymphocyte toxicity assay (LTA) to investigate idiosyncratic
reactions to aromatic anticonvulsants.
Type of study

No. of
patients

No. of
controls

Drug

a

b

Liver
microsome
species

Induction
with
phenobar
bital

Endpoint
measure
ment

Frequency of
positive result
(%)

Year/
Reference

Concentration

Time

N/A

N/A

mouse

+

MTT

SEN=92.9%

2008[103]

Cohort study

20

20

Phenytoin
Carbamazepine
Phenobarbital
Zonisamide

Case report

1

1

Lamotrigine

0-32 µg/ml

2 mo

N/A

?

N/A

1/1

2006[47]

Case series

11

11

Phenytoin

0-32 µg/ml

N/A

mouse

+

TB

11/11 (100%)

2004[105]

Case report

1

0

Phenobarbital

0-32 µg/ml

70 D

mouse

+

TB

1/1

2004[106]

Cohort study

62

24

N/A

N/A

mouse

+

MTT

SEN=98%

62

24

N/A

N/A

mouse

+

TB

SEN=91%

2000[102]

Cohort study

51

0

N/A

N/A

mouse

+

TB

49/51 (96.1%)

1994[104]

Case report

1

6

Carbamazepine

50 µmol/L

N/A

mouse

+

TB

1/1

1994[77]

Case series

3

c

59

Phenytoin

62.5 µmol/L

N/A

mouse

+

TB

3/3 (100%)

1991[107]

Case series

7

17

Carbamazepine

50 µM

N/A

d

Human

-

TB

7/7 (100%)

1

17

Carbamazepine
Oxcarbazepine

50 µM

N/A

Human

-

TB

1/1

34

59

Phenytoin

62.5 µM

N/A

mouse

+

TB

34/34 (100%)

25

59

Carbamazepine

62.5 µM

N/A

mouse

+

TB

21/25 (84%)

Cohort study

Phenytoin
Carbamazepine
Phenobarbital
Lamotrigine
Phenytoin
Carbamazepine
Phenobarbital
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1991[108]

No. of
patients

No. of
controls

Drug

22

59

Case series

2

Case series

3

Type of study

a

Concentration

Time

Phenobarbital

62.5 µM

N/A

20

Phenytoin

31-125
µmol/L

17

Phenytoin

31, 62, 125
µM

b

After
recove
ry
After
recove
ry

Liver
microsome
species

Induction
with
phenobar
bital

Endpoint
measure
ment

Frequency of
positive result
(%)

Year/
Reference

mouse

+

TB

21/22 (95.5%)

1988[1]

mouse

+

TB

2/2 (100%)

1986[39]

mouse

+

TB

3/3 (100%)

1981[40]

[a]: The suspected drug causing the reaction as suggested by at least the medical history.
[b]: time elapsed between the reaction and the test.
† : In this particular study 26.5% of control was positive.
[c]: siblings from the same family.
[d]: only two patients were tested acutely and there was no significant difference.
Abbreviations: E.P.= end point measurement, Ind.= induction with phenobarbitone, M = month, MIC Sp= liver microsome
species, TB= trypan blue, Wk = week, SEN = Sensitivity, Y = year.
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Table (3): Opportunities for technical improvement of the lymphocyte toxicity assay
(LTA).

80

Isolation and purification of surrogate model cells (PBMCs)
Reduction of the number of contaminating platelets
Use of platelets as a surrogate model
The metabolic activation system
Species difference in liver microsomes metabolic activity (human vs animals).
Use of induced vs. non-induced microsomes
Incubation conditions
Incubation time
Buffers and additives
End-point and measurement methods
Method of measurement of cell death
Other end-points (e.g., expression of other cell injury markers)
PBMCs=Peripheral blood monocytes

81

Cell death is the ultimate response of vulnerable cells exposed to the offending drug
as an insult. However, it is a gross measure of the cellular and sub-cellular events that
occur and may vary depending on the tested drug and the incubation conditions.[116] In
this regard, cell death is unlikely to be the best end point to indicate cell response to a
toxic insult. Finally, defining and obtaining the ultimate in vivo toxic metabolite(s) of the
offending drugs and their direct in vitro

testing will have a strong impact on the

predictability of the results of the LTA as the complicated metabolic activation step(s)
will be eliminated. This has been proven to be true in testing patients hypersensitive to
sulphonamides where the reactive metabolites can be tested directly to assist in test
validation.[117]
3.4. Discussion
AHS is a rare but potentially lethal disorder. One of most challenging aspects of this
disease is the difficulty to establish solid diagnosis in a timely manner.[2, 8, 118-121] Lack of
or misdiagnosis may result in increased morbidity, mortality and extended
hospitalization.[122, 123] Ten to 27% of patients with epilepsy discontinue their first antiepileptic drug because of the development of adverse reactions.[124] Aromatic
anticonvulsant drugs such as DPH, CBZ, PHB and LMG are linked to a relatively high
risk of for development of hypersensitivity reactions.[125] CBZ was found to be the
commonest cause of severe forms of AHS (i.e., SJS and TEN).[126]
The diagnosis of AHS entails two main processes: first, establishing diagnosis of
the hypersensitivity reaction, usually from a series of clinically similar differential
diagnoses, and second, identifying the culprit drug, potentially among a number of other
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concomitantly prescribed innocent ones. Numerous diagnostic tests are available and
have been attempted for the diagnosis of drug hypersensitivity reactions; however, their
epidemiological qualities are dependent on the type of reaction (immediate versus
delayed reactions) and type of drug, and choosing the best test for a specific drug or drug
class can be quite challenging.[7, 8, 37]
The LTT and LTA are two different approaches for AHS diagnosis and may
complement each other as a battery of diagnostic tests that can also include in vivo tests
such as the patch test and systemic rechallenge. The LTA may predict the susceptibility
of patients to develop AHS based on a genetic deficiency in their cellular defence
systems against toxic reactive drug metabolite(s), whereas the LTT may confirm the
development of AHS by detecting peripherally circulating drug-specific T-cells. It is
evident that these tests lack standardization and large scale validation to determine their
appropriations in terms of sensitivity and specificity in addition to positive and negative
predictive values.[31, 37, 48]
The sensitivity and specificity of the LTT in diagnosis of drug allergy has been
estimated to range from 56% to 78% and from 85% to 93%, respectively although these
estimates are generally based on cases of allergy to β-lactam antibiotics and cannot be
extended to other types of drugs.[37,

59]

In the diagnosis of AHS due to aromatic

anticonvulsants (AACs) the LTT has frequently shown a sensitivity between 71% to
100%[14, 51, 53, 57, 58, 62, 63, 67] but this range also as low as 19% to 40%.[55, 64, 65, 76] Estimates
of specificity, however, seem to be quite good (close to 100%).[51, 53] Nevertheless, one
must always keep in mind that these estimates have been calculated in the absence of a
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diagnostic gold standard, which may explain the considerable variability in these
numbers.
AHS has a broad range of clinical manifestations[127] reflecting differences in the
underlying pathophysiology.[91, 128] If the LTT is able to detect circulating drug-specific
T-cells, it is logical to expect that other “non-T-cell-mediated” reactions will not be
detected using this approach. Ironically, the LTT gave positive results with IgE-mediated
type I reactions which also imply a role for T-cells in these types of reactions.[67] In vitro
tests detecting antigen-specific IgE antibodies are also available and might be expected to
be more sensitive for these types of reactions.[8]
Reviewing publications on the use of the LTA as a diagnostic tool for AHS has revealed
a range of sensitivity between 85 to 100% with well documented AHS cases, with
satisfactory negative and positive predictive values. The LTA has also been shown to
possess good sensitivity in cases involving AHS due to sulphonamides[117,

129-131]

and

valproic acid.[132]
3.5. Conclusion
Analysis of peripheral blood lymphocytes has been a “promising” diagnostic tool
for HAS for several decades. It appears that without further understanding of the
mechanisms underlying the pathophysiology of AHS and how specific drugs and
metabolites differentially affect these mechanisms that the development of more reliable
tools for AHS diagnosis will be compromised. Consequently, in the absence of further
research the predictability of these tests will remain questionable and they are unlikely to
be utilized on a large scale.
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4.1. Introduction
The term adverse drug reaction (ADR) is defined as any noxious and unintended
response to a drug that occurs at a dose normally used in man for prophylaxis, diagnosis
or therapy.[1] Most ADRs are predictable, dose-dependent and related to the
pharmacological action of the drug (Type A), accounting for 75-80% of all reported
ADRs. The remaining 20 to 25% are defined as Type B-ADRs which are unpredictable,
unrelated to the known primary pharmacological action of the drugs and do not have a
clear dose-dependency.[2, 3] As they are patient-specific and unpredictable this type is also
titled idiosyncratic drug reactions (IDRs). Typically IDRs occur in a small fraction of
patients at the normal therapeutic dose and are unrelated to the primary pharmacological
action of the drug.[4] Unfortunately, the underlying mechanisms of IDRs are poorly
understood although a large portion of IDRs are believed to be immune-mediated, at least
in part, as delay in onset and rapid occurrence upon rechallenge are typical. [5] Drug
hypersensitivity syndrome (DHS) is considered one type of immune-mediated IDRs,
characterized by constellation of signs and symptoms that develop in susceptible patients
following exposure to certain drugs.[6] It is most commonly associated with the use of
NSAIDs,

aromatic

anticonvulsants

(AACs),

antibiotics

and

sulfonamides

antimicrobials.[7]
It has always been a challenge to establish the diagnosis of DHS due to lack of a
safe and reliable diagnostic test and because of its variable clinical picture. Another
challenge is the fact that, with the exception of fixed drug eruption (FDE), it can be
mimicked by other non-drug related illnesses (e.g., bacterial or viral infections).[4, 8, 9] In
addition to the importance of identifying susceptible patients to establish safe clinical
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practice it is essential not to falsely label a patient as hypersensitive to a drug which could
be otherwise therapeutically useful. This is especially important in cases where
alternative therapy is more risky or less effective (e.g., first line therapy for epilepsy or
allopurinol for gout). This warrants the development of safe and reliable test to confirm
diagnosis and identify the culprit drug.
We have recently performed systematic reviews to evaluate the usefulness of
different in vivo and in vitro diagnostic tests in the diagnosis of DHS due to aromatic
anticonvulsant drugs.[10, 11] These tests included the skin patch test (PT), the lymphocyte
transformation test (LTT) and the lymphocyte toxicity assay (LTA). It was quite evident
that the negative and positive predictive values of these tests were not clear, their
usefulness in clinical practice is controversial and that more research is needed to prove
or disprove their clinical usefulness. Systemic rechallenge or provocation test is
considered the „gold standard‟ in diagnosis of DHS. However, this approach is not
always ethically plausible due to potentially severe reactions that may develop.[8, 12, 13]
The lymphocyte toxicity assay (LTA) was first developed by Spielberg and colleagues in
the 1980s to investigate patient susceptibility to DHS [14-17]. The test is based on the
concept that DHS develops as a result of imbalance between activation (toxication) and
detoxication of drugs in vivo (the reactive metabolite hypothesis).[18] This hypothesis has
provided partial explanations on how some patients are „genetically‟ predisposed to
develop such reactions and others are not. Genetic polymorphism in enzymes involved in
both activation and detoxifications of drugs has been demonstrated in DHS patients and
healthy controls.[19-21] The test includes isolation of peripheral blood lymphocytes
(peripheral blood monocytes, PBMCs) from blood samples from patients and healthy
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controls and incubation of these lymphocytes with the culprit drug for 2 hours at 37°C in
presence of metabolic activation system (e.g., rat liver microsomes) in suitable media.
After overnight recovery period at 37°C cell viability is then measured using different
methods (Trypan blue exclusion method or MTT[3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] method).[14,

22]

It has been demonstrated that cells from

hypersensitive patients are more susceptible to cell death induced by incubation with the
culprit drug than cells from healthy controls. This observation has found a clinical
application for the diagnosis of DHS and identifying the culprit agent usually among a
group of suspected drugs.[17, 23, 24]
The main obstacle that hinders accurate determination of predictive values of this
test is lack of a safe gold standard test to measure it against. As a result, presently there is
very little clinical data to confirm the LTA after re-exposure.[10] In an attempt to close
this gap we performed this cohort study on a group of patients who had been tested using
the LTA for susceptibility to DHS. We aimed at identifying individuals who might have
deliberately or inadvertently been exposed to the culprit drug(s) after having been tested.
Our objective was to use these cases of re-exposure to calculate the negative and positive
predictive value of the test.
4.2. Methods
4.2.1. Patient recruitment and data collection
One hundred and forty seven patients were included in the study. These patients
had developed hypersensitivity reactions to different drugs and were tested using LTA
between 1991 to 2008 in two Drug Safety Clinics [Sunnybrook Health Sciences Centre
(SHSC), Toronto, ON and the Children Hospital of Western Ontario (CHWO), London,
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ON, Canada]. The drugs assessed included aromatic anticonvulsants (phenytoin,
carbamazepine,

phenobarbitone,

lamotrigine),

valproic

acid,

sulfonamides

(sulfamethoxazole, sulfasalazine and sulfapyrazine), β-lactam antibiotics (amoxicillin,
and cefaclor), macrolide antibiotics (erythromycin and clarithromycin), tetracycline,
codeine and accutane. Subjects were identified from their medical records at the two
locations. The inclusion criteria were: (1) the patient developed DHS as evaluated by the
clinic specialist; (2) the patient was tested for susceptibility to DHS using the LTA; and
(3) consent was obtained from the patient or parent (in case of children) to participate in
the study. Patients were excluded from the study if their files did not contain sufficient
information (contacts or LTA results) or they did not consent.
Ethical approval was obtained from the Research Ethics Boards of SHCS and the
University of Western Ontario and information letters were sent to each potential
participant prior to contacting them. Verbal consents were obtained from participants or
their parent (in cases of children patients) prior to inclusion in the study.
4.2.2. Preparation of rat liver microsomes
Adult Sprague Dawley rats (mean weight 200 g) were sacrificed by decapitation
and their livers were quickly isolated under aseptic condition and washed with ice cold
0.5 M potassium phosphate homogenization buffer. Livers were then diced with scissors
and homogenized in 3 volumes homogenization buffer using drill powered PotterElvehjem homogenizer. Homogenate were then centrifuged at 9000 g for 30 min at 4°C.
Supernatants were then centrifuged at 100,000 g for 1 hr at 4°C. The pellets were then
resuspended in homogenization buffer and stored at -80°C until used. Microsomal protein
contents were determined by the method of Lowry et al.[25]
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4.2.3. Blood collection and isolation of PBMCs
Blood samples from patients and healthy volunteers were obtained by
venepuncture, collected into heparinized syringes and separated immediately. To isolate
lymphocytes samples were diluted 1:1 with phosphate buffered saline (NaCl, 137 mM;
KCl, 2.7 mM; NaH2PO4, 10 mM; KH2PO4, 2 mM; pH of 7.4) and layered on a Ficoll® paque density gradient. Gradients were then spun at 500 g for 20 minutes, the aqueousFicoll interface layer was collected, washed twice with PBS and cell density was adjusted
to 1×106 cell per ml in 4-(2-hydroxymethyl)-1-piperazineethanesulfonic acid (HEPES)
buffered saline (HEPES, 15 mM; NaCl, 125 mM; KCl, 6 mM; MgSO4, 1.2 mM;
NaHCO3, 1.0 mM; CaCl2, 1.0 mM; glucose, 10 mM;pH 7.4). At this stage cell viability is
determined using trypan blue exclusion method and is always greater than 95%. All steps
are performed in an aseptic condition in a laminar flow hood.
4.2.4. The lymphocyte toxicity assay (LTA)
The LTA was performed as previously described.[14] Briefly, 100 µl of peripheral
blood monocytes (PBMCs, lymphocytes) suspension at density of 1×106 cell/ml were
placed in each well of 96-flat-bottom multiwell plates. Cells were incubated with the
either the drug (at concentrations ranged between 6.5 to 500 μM, aromatic
anticonvulsants; beta-lactam antibiotics) or its reactive metabolite (In sulfa cases at
concentration range 50 to 800 μM) for 2 hrs in humidified atmosphere at 37°C and 5%
CO2 partial pressure. In experiments where the parent drug is used the metabolic
activation system (rat liver microsomes, prepared as described above) was included in the
incubation media. Microsomal protein was added at concentration of 0.25 mg/ml
followed by addition of the NADPH generating system (NADP, 0.6 mM; glucose-6101

phosphate, 2.4 mM; glucose-6-phosphate dehydrogenase, 2 U/ml). Plates were then spun
down at 500 g for 15 minutes and media were replaced with fresh RPMI 1640 media
containing 10% FBS and penicillin/streptomycine cocktail. Cells were then let to recover
for 18 hrs in humidified atmosphere at 37°C and 5% CO2 partial pressure. At this point
plates were spun down and resuspended in 100 µl HEPES buffer. 25µl of 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at 5 mg/ml were added
each well and incubated at 37°C for 4 hrs and reactions were stopped by adding 100 µl
stop solution (NN-dimethylformamide, DMF, 50%; sodium dodecyl sulphate, SDS, 20%)
and allowed to set overnight at room temperature, protected from light. The absorbance
was measured at 590 nm by a Molecular Device Spectrophotometer (Beckman, Palo
Alto, CA, USA). A standard curve as generated by seeding the cells at 0, 25, 50, 75 and
100% of cell concentration in the corresponding buffer in quadruplicates. The data were
analyzed using the SoftmaxTM Molecular Device Group Analytical software version 2.35
and statistical graphs were created using Microsoft ExcelTM 2007 software. A cut-off
value of 15% increase in cell death over base line (control) was used to determine
positive tests. Patients were tested either in the lab of MJ Rieder at the University of
Western Ontario or in the Drug Safety Clinic at Sunnybrook Health Sciences Centre.
4.2.5. Follow-up interviews
Information obtained from patient medical charts included patient age, gender,
drugs tested, signs and symptoms of the reaction and LTA results. Participants were then
asked to answer a standard questionnaire through telephone interviews. The questionnaire
was designed to identify if the patient was exposed to the drug after being tested using the
LTA and to find out the clinical response to the re-exposure. Patients were also asked
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whether they have had allergic reactions to any other drugs or any family history of such
reactions. The data obtained was analyzed to estimate the test predictive values in the
diagnosis of DHS.
4.3. Results
One hundred forty seven patients ranging between 3 and 89 years of age (mean
30.1 year) consisted of 81 (55.1%) female and 66 (44.9 %) male were recruited. The LTA
was performed on these patients as following: for AACs (n=124), for sulfa drugs (n=72),
for β-lactam antibiotics (n= 76), for macrolide antibiotics (n=10), for ciprofloxacin
(n=3), for valproic acid (n=3), for accutane (n=2), and 1for tetracycline and codeine. The
LTA results were found to be negative in 179 tests (61.3%) and positive in 113 tests
(38.7%). The majority of patients avoided any use of the suspected drugs after the first
incidence regardless of the LTA test result. A subgroup of 22 patients had been exposed
to a tested drug out of 147 patients studied (15.0%). In total of 26 events of re-exposure
21 took place after a negative LTA and 5 after a positive LTA (Table 1).
The clinical data collected at the first incidences vary among patients, including
skin rashes (erythmatous or blistering), fever, edema, GIT, hepatitis, lung diseases,
lymphadenopathy and hematological abnormalities (Table 2).
Among the 26 cases of re-exposures in 22 patients 4 were true positive, 17 were
true negative, 1 was false positive, and 4 were false negative as determined by syatemic
re-exposure . Based on the limited number of re-exposure obtained the negative
predictive value (NPV) of the LTA in the diagnosis of DHS vary according to the drug
tested. Among 13 cases of re-exposure to β-lactam antibiotics 2 were true positives, 8
were true negatives and 3 were false negatives. This suggests low sensitivity and high
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specificity of the test in diagnosis of DHS due to these drugs. On the other hand,
sensitivity of the LTA in the diagnosis of DHS due to sulfonamides may be higher as no
false negative results were identified among the 7 cases of re-exposure. Five re-exposures
to aromatic anticonvulsants revealed 4 true negatives and 1 false negative. The overall
sensitivity and specificity of the LTA in the diagnosis of DHS based on our 22 cases are
estimated to be 40% and 90%, respectively.
4.4. Discussion
Drug hypersensitivity syndrome (DHS) is a rare disorder with high rates of morbidity and
mortality. It represents a challenging clinical problem and increases patient care cost.
While early diagnosis of DHS is essential for patient safety, that is not always achievable
due to lack of a safe and reliable diagnostic tests. The LTA has been a promising
diagnostic tool for such reactions but its clinical value has not been determined. To our
knowledge this is the first study to use a „gold standard‟ test (systemic re-exposure) to
validate the LTA. All previous attempts were based on correlation of suspected clinical
manifestations and history of exposure with the LTA test. Clinical manifestations of DHS
are quite variable and it is often difficult to associate a typical clinical picture to this
disease.[26] Furthermore, temporal relationship between administration of the suspected
drug and development of the disorder is known to be of poor predictive value especially
in cases where multiple drugs are used.[14]
Previous studies have attempted to measure the diagnostic value of the test.
Naranjo et al. (1994) evaluated the performance of LTA in diagnosis of drug
hypersensitivity reactions using a Bayesian statistical instrument to determine causality
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Table (1): Characteristics of patients with drug hypersensitivity syndrome (DHS).
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Characteristics

Value

Sex (female/male;n[%]

81/66 [55/45]

Age (mean;y[range])

30.1 [3-89]

Type of reaction
Skin rash only
Systemic involvement
None a

45 [31]
83 [56]
19 [13]

Drug tested b
Sulfonamides
Β-lactam antibiotics
Aromatic anticonvulsants
Others

72 [25]
76 [26]
124 [43]
20 [7]

a: These are either relatives to patients or their clinical data are unavailable.
b: patients may be tested for more than one drug.
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Table (2): Characteristics of systemically re-exposed patients, their lymphocyte toxicity
assay (LTA) results and results of re-exposure.
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Patient
no.

Age
(y)

Sex

Drug tested

LTA
result

Re-exposure

1

15

male

Amoxicillin

-

+

2

9

male

Amoxicillin

-

+

3

12

Female

Sulfamethoxazole

-

-

4

18

Female

Sulfamethoxazole

-

-

5

66

Female

Sulfamethoxazole

-

-

6

63

Female

Amoxicillin

-

-

7

23

Female

Cefaclor

+

+

8

62

Female

Sulfamethoxazole

+

+

9

10

Female

Amoxicillin

-

-

10

25

male

Sulfamethoxazole

+

-

Sulfamethoxazole

-

-

11

17

male

Cefaclor

-

-

12

17

male

Cefaclor

-

-

13

13

Female

Amoxicillin

-

-

14

22

male

Accutane

+

+

15

9

male

Cefaclor

+

+

16

12

male

Amoxicillin

-

+

17

52

Female

Phenobarbital

-

-

18

14

male

Phenytoin

-

-

19

82

Female

Carbamazepine

-

-

20

14

male

Phenobarbital

-

+

Lamotrigine

-

-

21

8

Female

Amoxicillin

-

-

22

11

Female

Sulfamethoxazole

-

-

Cefaclor

-

-

Amoxicillin

-

-

+ indicates a positive test result; - indicates a negative test result
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on 51 patients with suspected drug reactions. They estimated that LTA has a specificity
of 75% and sensitivity of 99% in their studied cases. However, their study still lacked a
„gold standard‟ measure such as systemic rechallenge.[27] In another study to validate the
LTA in diagnosis of DHS Neuman et al. (2000) studied 86 patients with suspected
reactions to sulfamethoxazole (SMX), 62 to anticonvulsants and 26 healthy volunteers.
They estimated the negative predictive value of the test to be 64% and the positive
predictive value to be 90% with sensitivity and specificity of 98% and 89%,
respectively.[22] However, no re-exposure data were available. In cases due to
sulfonamides we found that the test has high NPV. This is possibly due in part to the
simplified procedure to test for SMX which does not include in vitro metabolic
activation. The toxic metabolite of sulfa drugs has been identified and synthesized and
was found to be adequately stable to be used experimentally for the in vitro testing.[28]
This step has provided a more simplified and apparently more sensitive test. The PPV of
LTA in highly suspected cases of DHS due to SMX has been estimated previously to be
between 80% and 90% [29, 30]. However, in these studies the parent drug not the
metabolite was used in the in vitro toxicity testing. In our study, for drugs such as βlactam antibiotics (e.g., amoxicillin and cefaclor) however, the NPV was low which may
be explained by the more complicated pathophysiology of hapten-mediated reactions
caused by these drugs.[31] Previous studies have suggested that the performance of LTA in
cases of hypersensitivity to cefaclor depends largely on the type of reaction.[32] Due to the
retrospective nature of our study it was not possible to re-evaluate the patients clinically
or to classify them according to the type of reaction. Having included cases in our study
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with mixed types of reaction could be the cause for the relatively low NPV of LTA in βlactam antibiotics cases.
The low sensitivity of the LTA test in β-lactam antibiotic cases is probably due to
the complicated procedure of the test when using the metabolic activation system for
drugs that need to be metabolized to a reactive (cytotoxic) metabolite(s). This is further
supported by the good sensitivity of the test among SMX-induced cases.
Considering the lack of complete understanding of the pathophysiology
underlying DHS, it is difficult to speculate on how patient cells would react with the
suspected drug in vitro. Drugs such as β-lactam antibiotics are known to cause different
types of reactions and they are classical hapten forming agents.[33] Different molecular
mechanisms and requirements are thought to underlie each type of these reactions (i.e.,
Cell-mediated vs IgE-mediated) and some of them may not be detectable by the in vitro
LTA test.[6] Furthermore, the variable clinical picture of the DHS may lead to difficulty in
identifying affected patients. Among our cases 30.6% developed type of skin rash only
and 56.5% developed other systemic signs that included fever, hepatitis, respiratory
diseases, hematological abnormalities, gastroenteritis, facial edema, anaphylaxis,
angioedema, lymphadenopathy and serum sickness-like reactions.
It is well established that 50% of all drugs in common use may cause some type
of skin rash and that, in addition to fixed drug eruption, exanthematous (morbilliform,
maculopapular or scarlatiniform) and urticarial rashes are the more common cutaneous
adverse reaction.[34] Exanthematous and pustular eruptions are more commonly
associated with DHS as oppose to urticarial rash, which is usually caused by immediate
type (type I) hypersensitivity reactions. The pathophysiological mechanisms of both
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types of reactions are thought to be different.[6] Taken together, one may expect that the
LTA can have different predictive value in cases of both types of reactions; however,
positive LTA tests were observed in this cohort in cases with all spectrums of cutaneous
reactions (data not shown). This test detects the vulnerability of patient cells to the drug‟s
reactive metabolite(s). According to the reactive metabolite hypothesis, drug activation is
a pre-requisite for DHS to develop and this could be a common step in the cascade of
events that lead to the development of different type of reactions. This is one of the LTA
potential advantages; it detects the genetic susceptibility of the patient to develop DHS,
thus the test can be also used for patient screening prior to prescribing a potential
causative drug in high-risk populations.
Although the number of re-exposed cases was relatively low to allow comparative
statistics, our data provided a fair evaluation of the test performance in the diagnosis of
DHS based on the definite power of systemic re-exposure. There is no doubt that better
controlled prospective studies using more defined inclusion criteria are required to decide
on the true clinical value of this test; however, there are several technical and ethical
obstacles that should be overcome before such studies can be conducted.
We have demonstrated anther critical aspect of the LTA that deserve discussion.
From our data, it is evident that in most cases (88.3%) patients avoided reusing the
suspected drug (as probably per their doctors‟ advices) despite reassuring negative
results. This finding strongly suggests a situation of „mistrust‟ of the clinical value of the
test which is a direct result of the lack of evidence-based data on its predictive value. It is
unlikely that a diagnostic test with unknown predictive value will contribute to a better
clinical practice.
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The LTA can be a valuable diagnostic tool for patient susceptibility to DHS.
Although the currently used procedure is quite complex and requires specialized
experience. Further research may yield a more simplified test that is adaptable for wide
clinical use. Such research is driven by the urgent need for a safe and reliable diagnostic
test for DHS.
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5.1. INTRODUCTION
Adverse drug reactions (ADRs) account for 5% of all hospital admissions and
occur in 10-20% of hospitalized patients.1,2 Most ADRs (85-90%) are predictable, dosedependent and related to the pharmacological action of the drug (type A), but 10-15% are
unpredictable, unrelated to the pharmacological action of the drug and do not have clear
dose dependency (type B).3,4 A major category of the latter type is Drug Hypersensitivity
Syndrome (DHS).5,6 DHS is a rare but potentially fatal disorder that occurs in susceptible
patients following exposure to the culprit drug. It is most commonly associated with
aromatic anticonvulsants (e.g., phenytoin, carbamazepine, phenobarbital and lamotrigine)
and antimicrobials such as sulfonamides.5-7
It has been difficult to establish a diagnosis of DHS due to its variable clinical
presentation, overlap with other clinical conditions and the often delayed temporal
relationship between administration of the culprit drug and the appearance of symptoms. 8
Lack of a reliable and safe diagnostic test plays a major role in the significant morbidity
and mortality due to drug hypersensitivity.9,10 Other than systemic re-challenge with the
culprit drug, no gold standard diagnostic test is currently available. Unfortunately,
systemic re-challenge is ethically problematic.11 Currently available in vivo and in vitro
tests are not well characterized and their sensitivity and specificity are unknown.12,13
Attempts to develop safe and reliable in vitro diagnostic tests for DHS have been
underway for decades; however, recent systematic reviews of both in vivo and in vitro
diagnostic tests for DHS have documented a paucity of large scale studies to evaluate the
usefulness of these tests.14,15
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The lymphocyte toxicity assay (LTA) is an in vitro diagnostic test that was
developed

three

decades

ago

to

investigate

patient

susceptibility

to

drug

hypersensitivity.16,17 The usefulness of this test in diagnosing DHS is yet to be
determined as its negative and positive predictive values are still unclear.14 The main
disadvantage of this test is the lengthy and complicated method used to isolate peripheral
blood lymphocytes. This involves centrifugation of diluted blood samples over a gradient
of synthetic high molecular weight polymer of sucrose (Ficoll®) and isolation of a narrow
layer that contains lymphocytes, monocytes and a high number of attached and cosedimented platelets.18,19 This lengthy process complicates the assay, increases its cost
and may contribute to its poor reproducibility.
In an attempt to simplify and improve the LTA procedure, we have explored the
possibility to use another blood cell type as a surrogate cell model for the test. We
hypothesized that platelets would be a suitable candidate for this role. Platelets are
metabolically active non-nucleated cells derived from the cytoplasm of polyploid
megakaryocytes. They are 2.0 to 5.0 µm in diameter and 0.5 µm in thickness and
circulate in a density of 150-450×109 cell/liter in healthy individuals20 Because of their
small size and low density, platelets are very easy to obtain from peripheral blood
samples using simple differential centrifugation methods21,22 In addition to their well
known pivotal role in blood homeostasis and thrombosis, a great deal of evidence has
recently emerged on the role of platelets in inflammation, allergy and hypersensitivity
reactions, as well as having effects on immunity23-26 Platelets contain active mitochondria
and have a complete machinery for apoptosis which suggests that they may be a good
model to study cell toxicity.27-29 Furthermore, being unable to proliferate, platelets
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provide an extra advantage in accurately reflecting the degree of cell death upon exposure
to chemical insult, an effect that can be masked by cell replication in other proliferating
cell types (e.g. lymphocytes).
The present work is the first report on the use of blood platelets as surrogate cells
for in vitro toxicity testing of drugs. Data described here suggest that using platelets as
target cells may be a novel technique to predict the susceptibility of patients to develop
drug hypersensitivity.
5.2. MATERIALS AND METHODS
5.2.1. Chemicals
The hydroxylamine metabolite of sulfamethoxazole (SMX) was synthesized as
described previously,30 and determined by HPLC, mass spectrometry, and nuclear
magnetic resonance to be >99% pure. Carbamazepine, sulfamethoxazole, glucose-6phosphate, β-nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt
(NADP),

glucose-6-phosphate dehydrogenase (type XV from bakers yeast) and the

tetrazolium salt 3-(4, 5-dimethylthiazol-2-yl) 2, 5 diohenyl-tetrazolium bromide (MTT)
were purchased from Sigma-Aldrich Canada, Ltd. (Oakville, Ontario, Canada). All
remaining reagents were of analytical grade obtained from the usual commercial sources.
Drugs were prepared as stock solutions in dimethyl sulfoxide (DMSO) and diluted in the
used buffer to obtain the desired working concentrations. The final concentration of
DMSO in the media was always less than 0.2 %.
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5.2.2. Patients
Patients were selected according to the following criteria: 1) having a medical and
clinical history highly suggestive of DHS due to carbamazepine (CBZ) or
sulfamethoxazole (SMX) and/or 2) patients that had a positive LTA test to CBZ or SMX.
Blood samples were obtained from 8 individuals: two patients who had developed
hypersensitivity reactions (DHR) to drugs as suggested by medical history and clinical
manifestations; two patients who had never been exposed to the culprit drugs but were
diagnosed to be susceptible to DHR by the conventional LTA; and four healthy
volunteers who have denied any history of hypersensitivity reaction to the drugs or prior
exposure to the drugs. The patient group consisted of 3 adults (mean age 42.3 years) and
a child (9 years) who denied having been on any drug other than the suspected agent. The
study was approved by the University of Western Ontario research ethics board and
consent was obtained from participants or their guardians.
5.2.3. Blood collection and cells isolation
Blood samples from the patients and healthy volunteers were obtained by
venipuncture, collected into heparinized syringes and separated immediately. To isolate
lymphocytes, samples were diluted 1:1 with phosphate buffered saline (NaCl, 137 mM;
KCl, 2.7 mM; NaH2PO4, 10 mM; KH2PO4, 2 mM; pH of 7.4) and layered on a Ficoll®paque density gradient. Gradients were then spun at 500 x g for 20 minutes, the aqueousFicoll interface layer was collected, washed twice with PBS and cell density was adjusted
to 1×106 cell/ml in 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES)
buffered saline (HEPES, 15 mM; NaCl, 125 mM; KCl, 6 mM; MgSO4, 1.2 mM;
NaHCO3, 1.0 mM; CaCl2, 1.0 mM; glucose, 10 mM; pH 7.4). At this stage cell viability
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is determined using trypan blue exclusion method and is always greater than 95%. All
steps are performed in an aseptic condition in a laminar flow hood.
To collect platelets, blood samples were centrifuged at 200 x g for 15 minutes and
the platelet rich plasma was then centrifuged at 900 x g for 15 minutes to pellet platelets.
Platelets were then washed twice with modified calcium-free Locke‟s solution (NaCl,
154 mM; KCl, 2.6 mM; K2HPO4, 2.14 mM; KH2PO4, 0.85 mM; MgCl2, 1.2 mM;
glucose, 10 mM; and EGTA, 2.0 mM; pH 7.2) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) and cell density was adjusted to 7.5 × 108 cell/ml in calciumfree Locke‟s solution.
5.2.4. Preparation of rat liver microsomes (RLM)
Adult Sprague Dawley rats (mean weight 200 g) were sacrificed by decapitation
and their livers were quickly isolated under aseptic condition and washed with ice cold
0.5 M potassium phosphate homogenization buffer (pH 7.2). Livers were then diced with
scissors and homogenized in 3 volumes homogenization buffer using drill powered
Potter-Elvehjem homogenizer. Homogenate were then centrifuged at 9000 x g for 30 min
at 4°C. Supernatants were then centrifuged at 100,000 x g for 1 hr at 4°C. The pellets
were then resuspended in homogenization buffer and stored at -80°C until used.
Microsomal protein contents were determined by the method of Lowry et al. (1951).31
5.2.5. The in vitro toxicity assay
The conventional LTA was performed as described previously.6 Briefly, 100 µl of
peripheral blood monocytes (PBMCs, lymphocytes) suspension at density of 1×106
cell/ml were placed in each well of 96-flat-bottom multiwell plates. Cells were incubated
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with either the drug in question or its reactive metabolite for 2 hrs in humidified
atmosphere at 37°C and 5% CO2 partial pressure. In experiments where the parent drug
was used, the metabolic activation system was included in the incubation media.
Microsomal protein was added at a concentration of 0.25 mg/ml followed by the NADPH
generating system (NADP, 0.6 mM; glucose-6-phosphate, 2.4 mM; glucose-6-phosphate
dehydrogenase, 2 U/ml). Plates were then spun down at 500 x g for 15 minutes and media
were replaced with fresh Roswell Park Memorial Institute (RPMI) 1640 media containing
10% FBS and penicillin/streptomycine cocktail. Cells were then let to recover for 18 hrs
in humidified atmosphere at 37°C and 5% CO2 partial pressure. At this point plates were
spun down and resuspended in 100 µl HEPES buffer. 25µl of MTT at 5 mg/ml were
added to each well and incubated at 37°C for 4 hrs and reactions were stopped by adding
100 µl stop solution (N,N-dimethylformamide, DMF, 50%; sodium dodecyl sulphate,
SDS, 20% in DDH2O) and allowed to set overnight at room temperature protected from
light. Absorbance was measured at 590 nm by a Molecular Devices spectrophotometer
(Beckman, Palo Alto, CA, USA). A standard curve was generated by seeding cells at 0,
25, 50, 75 and 100% of concentration in the corresponding buffer in quadruplicates. The
data were analyzed using the SoftmaxTM Molecular Devices Group Analytical software
version 2.35 and graphs were created using Microsoft ExcelTM 2007 software.
The in vitro platelet toxicity assay (iPTA) was performed in a similar procedure
except that calcium-free Locke‟s solution was used as a medium in the experiments.
Platelets were incubated at density of 7.5×108 platelets/ml and plates were centrifuged at
900 x g in each step to pellet platelets.
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5.2.6. Microscopic examination of the platelet preparation
Samples from isolated platelets were spun onto glass slides using a bench-top
cytospin centrifuge, fixed in absolute methanol for 30 minutes and stained with WrightGiemsa stain for 20 minutes. They were then washed several times with distilled water,
mounted and visualized by phase-contrast under Olympus light microscope using oil
immerged objective (100X, 1.3 aperture).
5.2.7. Statistical analysis of data
Data were analyzed using Microsoft ExcelTM 2007 software and differences between
patients and controls were determined by t-test with Bonferroni correction for multiple
comparisons. Values are expressed as percentage of control (vehicle only) and presented
as mean ± standard error (SE).
5.3. RESULTS
5.3.1. Determination of platelets viability using MTT method
These experiments were carried out to determine whether cell death can be used as a
measurable in vitro end point for platelet susceptibility to reactive metabolites. Platelets
isolated from blood samples drawn from normal volunteers were incubated with different
concentrations (50, 100 and 200 µM) of sulfamethoxazole hydroxyl amine (SMX-HA,
the cytotoxic metabolite of SMX) for 2 hrs at 37°C and 5% CO2. At the same time
PBMCs isolated from the same samples were incubated under identical conditions side
by side. After incubation, media were replaced with fresh RPMI 1640 media and allowed
to recover for 18 hrs. The viability of both platelets and PBMCs was then determined
using MTT as described above. SMX-HA induces concentration-dependent cell death in
platelets in vitro in a similar manner as in PBMCs (figure 1). However, the cytotoxic
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metabolite induced more cell death in platelets at 100 and 200 μM (percentage: 18.9±4.5
and 44.5±6.6; respectively, n=12) than in PBMCs (percentage: 5.4±4.3 and 16.7±3.9;
respectively, n=12) (p<0.05). Platelets were able to convert the yellow tetrazolium to a
spectrophotometrically measurable blue formazan. Conversion of the tetrazolium to the
formazan depends on the activity of the mitochondrial succinyl dehyrogenase enzyme
indicating viability.32
To rule out the possibility that our platelet preparations may be contaminated with
other types of blood cells (e.g., erythrocytes), we performed microscopic examination of
samples from the isolated platelets. Slides from samples taken from platelet preparations
were prepared as described above and examined under a light microscope. At least
99.95% of cells observed were platelets confirmed by the characteristic morphology of
platelets (figure 1, insert).
5.3.2. Comparison of induction of cell death between PBMCs and platelets from
hypersensitive patients and healthy controls
We isolated PBMCs and platelets from 2 patients who had been diagnosed as
susceptible to developing hypersensitivity reaction to SMX using the LTA. In parallel
blood samples were withdrawn from 2 healthy volunteers with no history of exposure or
hypersensitivity reaction to SMX. Platelets and PBMCs from both groups were incubated
with increasing concentrations of SMX-HA (0-400 µM) and cell viability was then
measured using the MTT method as described above.
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Figure (1) Peripheral blood monocytes (PBMCs) (empty circles) and platelets (solid
circles) from healthy volunteers were isolated and incubated with increasing
concentrations of sulfamethoxazole hydroxylamine (SMX-HA). Cell death was then
determined using the MTT method and expressed as percentage of control (vehicle
without drug). Values are presented as mean±S.E. of at least 12 replications. Insert:
Samples from platelets preparations were spun onto glass slides, fixed, stained with
Wright-Giemsa stain and visualized under Olympus light microscope equipped with
100X objective lens (1.3 aperture). The figure shows a representative picture. Arrows
indicate small platelet aggregates.*, p<0.05.
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Figure (2) PBMCs (A) and platelets (B) from a healthy control (white bars) and from
SMX-hypersensitive patient (shaded bars) were isolated and incubated with increasing
concentrations of SMX-HA and cell death was then determined using the MTT method
and expressed as a percentage of control (vehicle without drug). C: Platelets from a
healthy control (white bars) and from a clinically suspected SMX-hypersensitive patient
(shaded bars) were isolated and incubated with increasing concentration of SMX-HA or
800 µM SMX and cell death was then determined using MTT method and expressed as
percentages of control (vehicle without drug). D: Platelets from a healthy control and a
clinically suspected CBZ-hypersensitive patient were isolated and incubated with either 0
µM or 250 µM CBZ in presence or absence of rat liver microsomes (RLM). Values are
presented as mean±S.E. of at least 6 repitations from each subject. PBMCs, peripheral
blood monocytes; SMX, sulfamethoxazole; SMX-HA, sulfamethoxazole hydroxylamine;
CBZ, carbamazepine; RLM, rat liver microsomes. *, p<0.05.
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As anticipated, incubation of PBMCs from a patient with SMX hypersensitivity
induced a concentration-dependent increase in cell death higher than in PBMCs isolated
from a healthy volunteer which was statistically significant at all concentrations tested
(p<0.05) (figure 2A). At 400 µM SMX-HA, for instance, the percentage of cell death was
29.1±1.0 (n=12) in PBMCs from a healthy volunteer vs. 67.6±1.2 in PBMCs isolated
from an SMX hypersensitive patient with a difference of around 38.5% (p<0.05). When
platelets isolated from the same hypersensitivity patient and healthy volunteer were
incubated with increasing concentrations of SMX-HA (0-400 µM) the difference in
induction of cell death was higher and significant at all concentrations tested (p<0.05)
(figure 2B). As a comparison to PBMCs the percentage of induction of cell death at 400
μM SMX-HA in platelets from the patients was 94.4±5.2 (n=12) and in platelets from the
healthy volunteer was 42.9±1.1 (n=12) with a difference of around 51.5%, suggesting
that the platelet test is more sensitive than the conventional LTA.
5.3.3. Response of platelets from a clinically suspected hypersensitive patient
Blood samples were taken from a 58-year old woman who had developed high fever
after taking a course of SeptraTM (sulfamethoxazole/trimethoprim) in the past and from
one healthy volunteer with no sulfonamide exposure. Platelets from the SMX
hypersensitive patient exhibited more cell death than platelets from the healthy volunteer
(figure 2 C) (p<0.05, with 6 samples from each). In fact, at 400 µM SMX-HA almost
100% cell death was observed in platelets from the hypersensitive patient (figure 2 C). In
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contrast, incubation of platelets from the patient and control with up to 800 µM SMX (the
parent drug) did not induce a significant amount of cell death (p = 0.4).
5.3.4. Response of platelets from a carbamazepine (CBZ)-hypersensitive patient to
RLM-generated toxic metabolite(s) of CBZ
Platelets from a patient who had clinical symptoms suggestive of hypersensitivity
reaction after exposure to CBZ, and from one healthy volunteer, were incubated with 250
µM CBZ in the presence (+RLM) and absence (-RLM) of rat liver microsomes and
NADPH-generating system as described above. Each test was repeated on 6 samples to
identify intra-test reproducibility. In the patient‟s platelets there was around 20% increase
in cell death in the presence of microsomes and NADPH-generating system compared to
platelets from the healthy volunteer (cell viability: 84±3.9 and 106± 0.73; respectively,
p<0.05, n=12) (Figure 2 D). Neither platelets from the healthy volunteer under both
conditions (-RLM or +RLM) nor platelets from the patient incubated without microsomes
(-RLM) shown any increase in cell death compared to control (vehicle without drug).
5.4. Discussion
The pathophysiology underlying drug hypersensitivity is not well understood.
However, several mechanistic frameworks have been introduced including the hapten
hypothesis and the reactive metabolite hypothesis.8,33 The latter hypothesis assumes that
drug hypersensitivity reactions develop as a result of imbalance between bioactivation
and detoxification processes of drugs in the body. Mechanistic studies using in vitro
cellular model have shown that certain phase I oxidation enzymes appear to be
responsible for generation of toxic metabolites which can then induce cell death in
vitro.34 It has been shown that PBMCs from hypersensitive patients and their family
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members are more susceptible to cell death upon exposure to the culprit drug (or its
metabolites) than cells from healthy subjects.6,35
A common property of most drugs implicated in eliciting DHS is their being
extensively metabolized to more reactive and cytotoxic species, such as aromatic
anticonvulsants (AACs) and sulfonamides.36 Although the culprit metabolite(s) of AACs
is/are yet to be identified, many in vivo and in vitro investigations have suggested arene
oxide derivatives of these aromatic compounds are the culprits.37-39 These species are
chemically short lived, highly reactive and capable of modifying intracellular
macromolecules (DNA, proteins) which can then act as haptens activating the immune
system.33 A major obstacle in in vitro toxicity testing of AACs is the unavailability of
these suspected “reactive” metabolites for quantification and study due to their instability.
Using the metabolic activation system (liver microsomes) to generate these metabolites in
vitro is a complicated process which presently lacks both standardization and
reproducibility.40 The sulfonamide sulfamethoxazole (SMX) is metabolized in vivo to
several primary and secondary metabolites including hydroxylamine (HA) derivative by
cytochrome P 450 (CYP) 2C9 and myeloperoxidase (MPO) enzymes. This metabolite
can undergo auto-oxidation to form the protein reactive nitroso species that is capable of
covalently binding to cellular macromolecules, causing direct cell death and forming
hapten complexes that can evoke immunological reactions.41 Rieder et al. (1988)30
synthesized and used sulfamethoxazole hydroxylamine (SMX-HA) for in vitro
rechallenge of lymphocytes from patients to determine their predisposition to
hypersensitivity reactions to sulfonamides.
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Data presented here introduce and characterize for the first time an in vitro platelet
toxicity assay (iPTA) which employs peripheral blood platelets as a surrogate model to
test for patient susceptibility to DHS. The iPTA may have advantages and potential
applications in clinical settings due to its low cost and simple procedure. Compared to
PBMCs, we show that platelets from hypersensitive patients not only respond similarly,
but the degree of cell death was greater and easier to detect than in PBMCs (figure 2 A
and B). This observation can be explained by the fact that platelets do not proliferate as
lymphocytes do, avoiding potential masking of cell death. In addition, platelets lack
nuclei and capacity for protein synthesis that compromises their defense against reactive
metabolite effects (e.g., glutathione S-transferase and glutathione contents can be easily
exhausted).
We observed different degrees of cell death after exposure of platelets isolated from
different individuals (figures 2 B and C). This can be attributed to difference in
sensitivity of the target cells. Susceptibility of the cells to in vitro toxicity is probably not
all-or-none but rather a graded response which is observed in testing different patients. 42
The question whether there is a certain threshold or level at which a reaction may develop
is difficult to answer given that DHS involves several cascades of events leading to the
clinical manifestations, and multiple mechanisms that may underlie the disease. A much
larger study with more strictly defined clinical cases will be useful in answering this
question.
A number of reports have recently documented a role for platelets in allergic
inflammation, hypersensitivity reactions and modulation of leukocyte function.23,25,43,44
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This provides further support for the rational of using platelets as a model cell for in vitro
testing of hypersensitivity reactions. Historically, Comaish (1968) tested patients with
suspected drug allergy using peripheral platelets and the increase in the release of radiolabeled serotonin (5-HT) as an end-point.45 Abnormal cellular response was also
observed after incubation of washed platelets from aspirin-sensitive asthma with NSAID
drugs in vitro.46
In summary, our studies document for the first time that platelets react in a manner
similar to PBMCs in response to AACs and sulfonamides. They are easy to obtain from
small blood samples, and do not proliferate, which makes them ideal for cytotoxicity
assays in vitro. As well, they contain the full apoptotic machinery to explore molecular
mechanisms of cell death. More research with larger groups of patients is needed to
confirm our findings. The new assay was established by us in single cases of CBZ and
SMX severe ADRs showing excellent intra-assay reproduciability and significant
differences from controls. We are now collecting multiple cases to validate the assay in
the near future for both drugs.
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Chapter 6. Severe bullous hypersensitivity reactions after exposure to
carbamazepine in a Han Chinese child with a positive HLA-B*1502 and a negative
lymphocyte toxicity assay: Evidence for different pathophysiological mechanisms.

This Chapter has been published previously:
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Severe bullous hypersensitivity reactions after exposure to carbamazepine in a HanChinese child with a positive HLA-B*1502 and negative in vitro toxicity assays:
evidence for different pathophysiological mechanisms.J Popul Ther Clin Pharmacol.
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6.1. Introduction
Drug hypersensitivity syndrome (DHS) or drug rash with eosinophilia and systemic
symptoms (DRESS) is a life-threatening type of adverse drug reaction (ADR). It is
unpredictable, unrelated to the drug‟s direct pharmacological action and does not have a
clear dose-effect relationship. These features put DHS among type-B (bizarre) ADRs as
opposed to Type-A (augmented) reactions, which are predictable from the
pharmacological action of the drug, and are dose-dependent.1 DHS is defined as a
constellation of symptoms that may include fever, skin rash and internal organ
involvement following drug exposure.2 The true incidence of DHS is unknown; however,
some authors have reported a rate as high as 13.5% of all ADRs.3,4 The lack of a clear
clinical definition for this disorder and the absence of any safe, validated diagnostic test
have limited the ability to confirm this type of ADR, and may have contributed to the
significant morbidity and mortality related to delayed diagnosis.
The clinical manifestations of DHS can be quite diverse, ranging from mild selfresolved maculopapular eruptions to severe life-threatening cutaneous reactions involving
multi-system dysfunction.5 The reactions may also take the form of a severe bullous skin
eruption with systemic involvement (e.g., Stevens-Johnson syndrome, SJS and toxic
epidermal necrolysis, TEN) with a mortality rate of up to 40%.6 The DHS spectrum has
also been classified according to the type of skin reaction: bullous cutaneous ADRs
(cADRs), which include SJS; and TEN and non-bullous cADRs, which include other
types of reactions that comprise DHS. The diagnostic criteria of DHS have been a subject
of lengthy debate, notably as to whether the severe forms of the disorder are variants of
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the same syndrome or completely different pathological entities.7,8 The nomenclature of
DHS is far from consensus; however, for the purpose of this study we have used „nonbullous CBZ-DHS‟ to indicate carbamazepine-induced hypersensitivity syndrome that is
not SJS or TEN. The latter are denoted as CBZ-SJS/TEN.
The lymphocyte toxicity assay (LTA) is an in vitro diagnostic test that has been used
for decades to investigate patient susceptibility to DHS.9 The test is based on the
hypothetical framework that susceptible patients have diminished ability to detoxify
reactive electrophilic metabolites of the culprit drugs (or more recently reactive
electrophilic by-products formed during the metabolism of the drug such as the lipid
peroxidation product, 4-hydroxynonenal); and thus, form them at amounts that can cause
DHS (the reactive metabolite hypothesis), presumably by the development of misdirected
immune response. The latter hypothesis has been applied to clinical cases for the
diagnosis of DHS.10,11
Several lines of evidence exist supporting the genetic basis of patient susceptibility
to DHS. Familial occurrence of DHS has been documented with cells isolated from
relatives of patients that are also susceptible to in vitro toxicity.9,12 Other evidence comes
from the discovery of an association between the existence of certain HLA alleles and
patients‟ susceptibility to DHS induced by drugs such as the anti HIV reversetranscriptase inhibitor, abacavir and the antiepileptic, carbamazepine (CBZ).13,14 These
findings also strengthened the proposed immunological etiology of DHS as genetic loci
within the major histocompatibility complex (MHC) region have been suggested to be
involved. One of the strongest associations was found between the susceptibility to CBZ141

induced SJS/TEN (CBZ-SJS/TEN) in Han Chinese patients and the occurrence of the
HLA-B*1502 allele.13,15 This genetic variation has 100% sensitivity and 97% specificity
for prediction of severe bullous reactions due to CBZ exposure in Han-Chinese
populations. This discovery has prompted the US-FDA to issue a recommendation to test
any patient with Asian ancestry for the HLA-B*1502 allele before initiating CBZ
therapy.16 It appears, however, that having the HLA-B*1502 allele is predictive of only
severe bullous reactions in the Southeast Asian population to CBZ.17 Of note, other
studies have not found any association between this specific genetic marker and the
disease in other ethnic groups.18-20
To the best of our knowledge, the present study is the first to attempt to unravel the
complexity of DHS pathogenesis using both genetic and biochemical evidence.
6.2. MATERIALS AND METHODS
6.2.1. Case Report
An 11 year-old boy with epilepsy of Han-Chinese origin presented to our Emergency
Department with SJS after receiving CBZ treatment for 2 weeks. He had previously been
treated with phenobarbital (PHB) for more than a year. The ADR started with fever and rash
that rapidly progressed to significant cutaneous and corneal involvement.
Dermatological examination confirmed mucosal ulceration followed by
maculopapular rash on the trunk, face and arms progressing to confluent macules
covering more than 50% of the body with extensive bullae and erythematous vesicles on
peripheries, and epidermolysis of 10% of body surface area, requiring skin debridement
by a plastic surgeon. Ophthalmological examination revealed bilateral epithelial defects
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and blurred vision. Blood haemoglobin content was 126 g/L, but dropped to 61 g/L on
day 5 requiring transfusion (2 units of blood). C-reactive protein (CRP) content was 84.9
mg/L. There was also mild elevation of liver enzymes in the plasma, (ALT, 325 U/L;
Amylase, 389 U/L; AST, 375 U/L; LDH, 1941 U/L) and transient hyperglycemia.
Serology showed negative IgM for CMV and Mycoplasma pneumonia. The boy was
treated with IVIG 1g/kg/day for 3 days, corticosteroid eye drops, and surgical
debridement of bullae. He recovered well and was discharged from hospital. The
Research Ethics Boards of the University of Western Ontario and the Hospital for Sick
Children approved this study.
6.2.2. HLA Typing
HLA-A, B, C and DR low resolution typing was performed using polymerase chain
reaction-sequence-specific oligonucleotide (PCR-SSO) method and HLA-B*15 and
Cw*08 high resolution typing was performed using polymerase chain reaction-sequence
specific primer (PCR-SSP) method (Toronto Regional Histocompatibility Laboratory,
Toronto, ON, Canada).
6.2.3. In vitro Toxicity Testing
The lymphocyte toxicity assay (LTA) was performed as described previously.9 Briefly,
100 µl of a peripheral blood monocyte suspension (PBMCs, lymphocytes), at a density of
1×106 cell/ml, were placed in each well of 96-flat-bottom multiwell plates. Cells were
incubated with different concentrations of CBZ for 2 hrs in a humidified atmosphere at
37°C and 5% CO2 partial pressure. Microsomal protein (0.25 mg/ml) was added followed
by an NADPH generating system (NADP, 0.6 mM; glucose-6-phosphate, 2.4 mM;
glucose-6-phosphate dehydrogenase, 2 U/ml). Plates were then spun at 500 g for 15 min
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and media was replaced with fresh RPMI 1640 media containing 10% FBS and
penicillin/streptomycin cocktail. Cells were allowed to recover for 18 hrs in a humidified
atmosphere at 37°C and 5% CO2 partial pressure. At this point, plates were spun down
and contents resuspended in 100 µl HEPES buffer. An aliquot (25µl) of a 5 mg/ml
aqueous solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was added to each well and incubated at 37°C for 4 hrs. Reactions were stopped
by adding 100 µl stop solution (50% N, N-dimethylformamide, DMF; sodium dodecyl
sulphate, SDS, 20%) and allowed to set overnight at room temperature, protected from
light. The absorbance was measured at 590 nm by a Molecular Device
Spectrophotometer (Beckman, Palo Alto, CA, USA). A standard curve was generated by
seeding the cells at 0, 25, 50, 75 and 100% of cell concentration in the corresponding
buffer in quadruplicate. The data were analyzed using the SoftmaxTM Molecular Device
Group Analytical software version 2.35 and statistical graphs were created using
Microsoft ExcelTM 2007 software.
The in vitro platelet toxicity assay (iPTA) was performed in a similar procedure as above
except, calcium-free Locke‟s solution was used as the medium in the experiments.
Platelets were incubated at a density of 7.5×108 cells/ml and plates were centrifuged at
900 x g, in each step to pellet platelets.
6.2.4. Statistical Analysis of Data
Data were analyzed using Microsoft ExcelTM 2007 software and differences between
cells from the patient and those from controls were determined by Student‟s t-test with
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Bonferroni correction for multiple comparisons. Values are expressed as percentage of
control (vehicle only) and presented as mean ± standard error (SE).
6.3. RESULTS
We performed the in vitro toxicity assays using cells from healthy volunteers and
the patient 3 months and 9 months after his recovery from the reaction. The patient‟s cells
(PBMCs, LTA and platelets, iPTA) did not show any significant increase in cell death
upon incubation with up to 250μM CBZ in the presence of fortified rat liver microsomes
(RLM) compared to healthy controls (Table 1). We performed an identical in vitro
toxicity assay to cells of a Caucasian patient who had typical non-bullous DHS to CBZ
(non-bullous CBZ-DHS). Cells from the non- bullous CBZ-DHS
patient showed a significant increase in cell death (~20%) upon exposure to CBZ and its
metabolites compared to cells from the healthy volunteer (p<0.05, n=12) (Table 1).
Genotyping for HLA-A, B, C and DR and for HLA-B*15 and Cw*08 revealed that the
CBZ-SJS Chinese patient carries the HLA-B*1502 allelle.
6.5. DISCUSSION
Aromatic anticonvulsants (AACs) are one of the drug classes most commonly associated
with DHS.21 They include clinically important drugs such as Phenytoin (DPH),
Carbamazepine (CBZ), Phenobarbital (PHB) and Lamotrigine (LMG). CBZ is the drug
of choice as first line therapy for certain types of epileptic seizure, including partial
seizures and tonic-clonic seizures. CBZ is also used to treat chronic pain and certain
psychiatric disorders. Carbamazepine-induced DHS is characterized by variable clinical
presentations and different degrees of severity. The condition can present as
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TABLE 1 Results of in vitro toxicity testing of CBZ-SJS patient, CBZ-DHS patient and healthy
controls
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In vitro toxicity testing

Time of the in vitro
Subject
toxicity assaya

LTA

iPTA

CBZ-SJS Patient

NEGb

NEG

Healthy control

NEG

NEG

CBZ-SJS patient

NEG

NEG

Healthy control

NEG

NEG

CBZ-DHS patient

POS

POS

Healthy control

NEG

NEG

3 months

9 months

3 months

a: Time elapsed between the reaction and the test. b: To determine test result we used 20%
increase in cell death as a cut-off value, see Method section for details; LTA- lymphocyte
toxicity assay; iPTA- in vitro platelet toxicity assay; CBZ- carbamazepine; SJS- Stevens
Johnson syndrome; DHS- drug hypersensitivity syndrome.
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maculopapular skin rash that may be accompanied with fever and other systemic
symptoms in virtually any organ. The disease can also develop as a severe bullous
reaction that involves skin, mucosal membranes and ocular tissue (SJS and TEN).
Carbamazepine and its oxidative metabolites can activate T-cells from DHS
patients in vitro22,23 and both CBZ and its major metabolite, CBZ-epoxide, yield a
positive patch test in CBZ-hypersensitive patients.24,25 Carbamazepine-specific CD4+,
CD8+ and CD4+/CD8+ T-cell clones have been generated in vitro from blood samples of
CBZ-hypersensitive patients.26 In light of the currently available data, it may be naive to
define CBZ-induced hypersensitivity reactions as a constellation of symptoms ranging
from simple maculopapular skin rash with fever to severe bullous skin manifestation with
multisystem dysfunction; as this definition does not address the distinct histopathological
and immunological features of different forms of CBZ-induced hypersensitivity
reactions. Additionally, genetics may play a major role in determining the susceptibility
of patients to CBZ-induced hypersensitivity reactions, because of their familial and ethnic
occurrence, as certain types of AACs-induced hypersensitivity reactions were found to
run in families.12,20,27
The search for genetic markers for ADRs has been underway for a long time and was
accelerated by the recent improvement in quality and decreased cost of gene analysis
methods. Because it was known that metabolic bioactivation plays an essential role in the
development of some hypersensitivity reactions, the first candidates were genes that
control the main metabolic enzymes (e.g., cytochrome P450 monooxygenases (CYP) and
epoxide hydrolase (EH)). However, studies have failed to identify any association
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between DHS and polymorphism in genes encoding these drug metabolizing
enzymes.9,15,28 Subsequently, attention was focused towards genes involved in immune
response, such as the HLA gene, which encodes the major histocompatibility complex
(MHC), a major player in the antigen presentation process.29 A number of HLA alleles
were found to be associated with hypersensitivity reactions to different drugs; however,
the strongest association was found between the HLA-B*1502 allele and the
development of CBZ-SJS/TEN in Southeast Asian populations, with an odds ratio of
2504.13 This allele was also found in high frequency in these populations, which may
explain the higher prevalence of SJS/TEN cases due to CBZ use among Southeast
Asians.17 This finding suggests a functional role of the HLA-B*1502 allele in CBZSJS/TEN pathogenesis, a hypothesis that is not yet proven.27
The cases presented here provide further biochemical and genetic insights into the
distinct pathogenesis of non-bullous CBZ-DHS and CBZ-SJS/TEN. A clinically
confirmed typical case of CBZ-induced SJS (according to the international standard
criteria30,31) in an HLA-B*1502 allele positive patient of Han Chinese origin represented
a useful opportunity to investigate the latter assumption. We have also tested a typical
non-bullous CBZ-DHS Caucasian patient. Our biochemical approach using two in vitro
testing systems revealed unexpected results (Table 1). We believe that our data are
consistent with distinct pathophysiological pathways within subsets of CBZ-DHS.
Specifically, in this case the immunological pathway is active whereas the toxic
metabolite pathway is not.
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Several working hypotheses have been proposed to explain the pathophysiological
mechanisms underlying DHS. The first to be introduced was the hapten hypothesis (HH),
which assumed that a small drug molecule can be recognized by the immune system only
after forming an adduct with endogenous peptide.32 The reactive metabolite hypothesis
attributes DHS to imbalance in bioactivation and detoxication of the drug resulting in
larger quantities of toxic metabolites in the body.10 The danger hypothesis considers
signals released by stressed and dying cells (e.g., cytokines, HSP, NO, ROS) as a
requirement to fully activate an immune response.33 Finally, the pharmacological
interaction with immune receptor hypothesis (p-i Hypothesis) has proposed another scenario
to activate the immune system by a small molecule. It postulates that drug molecules (parent
drug or metabolites) can directly bind non-covalently to T-cell receptors (TCRs) and activate
T-cells independent of gene processing and presentation.34
Undoubtedly, activation of the drug to an active metabolite is a prerequisite to
initiate a cascade of events leading to development of DHS. As depicted in Figure 1,
activation of the parent drug to an electrophilic reactive metabolite is likely to represent
the first step in a cascade of events leading to the ADR. Several lines of evidence
strongly suggest that metabolic activation is the first step in DHS.35 Cells (peripheral
blood monocytes, PBMCs and platelets) from drug hypersensitive patients are more
susceptible to the in vitro toxicity of the toxic drug metabolites than are cells from
healthy control individuals.11,36,37
Enhanced in vivo concentrations of the toxic metabolites fit well with the suggested
DHS mechanism. First, high level of cytotoxic reactive metabolites in either the
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metabolizing cells (e.g., hepatocytes or skin cells) or other tissues can cause cell necrosis
and death providing „danger signals‟ to prime antigen presenting cells (APCs) and T-cells
to be activated. These signals can be in the form of cytokines, HSP, NO or ROS released
from necrotic or apoptotic cells. Second, these „dying‟ cells can also release haptenated
proteins and peptides which can be processed by the APCs and presented as antigens.
Finally, the metabolites can interact directly with the T-cells receptors (TCRs) and form a
bridge with the MHC (class I and II) on APCs causing T-cell activation and expansion of
T-cell clones (the p-i hypothesis).34 It must be pointed out that these various hypotheses
are not mutually exclusive. Thus, the formation of ROS can result in the production of 2hydroxynonenal, an endogenous electrophile that could mimic a drug in terms of covalent
reaction with proteins, and enhance the immunological response and the severity of an
ADR.38
According to the classical theory of antigen presentation, activated APCs carrying the
antigen will migrate to a local lymph node and present the antigen in the context of the
MHC (classes I and II) to naive or memory T-cells which will then expand and initiate
the immune response.39 Antigens formed in the cytosol of APCs are presented on MHC I
to CD8+ cytotoxic T-cells; whereas, extracellular antigens are presented on MHC II to
CD4+ helper T-cells. Each of these types of immune response has its own characteristic
pathway and cytokine profile and can result in distinct clinical manifestations.23,39,40
Accordingly, the subsequent events along the pathway are determined by the expansion
of specific T-cell clones that will propagate the immune response and determine the
clinical signature of the reaction.41
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CD8+ T-cells are known to produce cytokines such as IFN-γ and TNF-α, which
increase the surface expression of MHC, and their cytotoxic effects are thought to be
mediated by Fas death receptor through increasing the expression of its legend FasL or by
a perforin/granzyme B dependent pathway.42 These mediators are highly expressed in
skin from SJS/TEN patients.43 On the other hand, CD4+ T-cells produce IL-4 and IL-5
leading to eosinophil recruitment and features characteristic of non-bullous DHS.
However, it is noteworthy that most of the details of DHS signalling pathways are
unknown at the present time, in part because of the lack of validated animal models for
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Figure 1: The reactive metabolite, hapten, danger and p-i hypotheses and their suggested
involvement in DHS. When a lipophilic drug molecule enters a biological system it will,
in most cases, be readily metabolized to either chemically reactive or non-reactive
metabolites. The reactive metabolites are in turn converted to less toxic or non-toxic
products. An imbalance in these processes can result in the enhanced concentration of
reactive toxic metabolites in vivo that can cause either necrotic or apoptotic cell death,
releasing the „danger signals‟ and haptenated self-peptides that can be processed by
specialized antigen presenting cells (APCs) and presented to specific T-cell clones. These
T-cell clones expand upon activation and mediate the immune response (see text for more
details). Certain alleles that were found to associate with a high risk of CBZ-DHS are
presented in boxes along the pathway. CBZ: carbamazepine, APCs: antigen presenting
cells, MHC, major histocompatibility complex.
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these types of reactions.44 It is unlikely that CBZ works only as a classic hapten-forming
drug (e.g., penicillin‟s) because penicillin‟s can induce all types of hypersensitivity
reactions in the „Coombs and Gell‟ classification (types I-IV)45 whereas CBZ induces
only type IV reactions.46,47 Furthermore, no endogenous immunologically-relevant
protein target has been identified to be haptenated by CBZ metabolites.
The recent finding of genetic predisposition to CBZ-SJS/TEN (but not non-bullous
CBZ-DHS) in individuals from Southeast Asian suggests a difference in the
pathophysiology of these two variations of ADRs caused by CBZ. This concept is
supported by our current study in which a Han-Chinese descendent with CBZ-SJS and
positive HLA-B*1502 allele was negative to both LTA and iPTA in vitro toxicity assays.
We earlier reported that LTA has a sensitivity of 85-100% in well documented CBZDHS cases.48 Such a finding strongly suggests that the severe bullous reactions caused by
CBZ (CBZ-SJS/TEN) may have distinct pathophysiology from non-bullous CBZ-DHS,
which is not detected by these in vitro toxicity assays.
It is apparent that hypersensitivity reactions (bullous and non-bullous) have different
pathophysiological mechanisms. Individuals prone to form enhanced concentrations of
toxic metabolites of drugs that cause ADRs may also carry genes that predispose to
immunotoxicity from metabolite-protein or by-product-protein adducts. While these
variables might co-exist in individuals with a high frequency of HLA-B*1502 allele, such
as is the case for Southeast Asians, development of CBZ-SJS/TEN in patients who carry
the HLA-B*1502 allele does not seem to depend on reaching a threshold of reactive
metabolites.
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Another feature that differentiates non-bullous reactions from SJS/TEN is the
involvement of viral reactivation, particularly human herpes virus 6 (HHV-6) which has
been observed in most non-bullous DHS cases but is not observed in SJS/TEN cases.7,49
This has led some investigators to establish HHV-6 reactivation as one of the diagnostic
criteria of DHS.50
Overall, these observations suggest that the process of activating APCs and antigen
presentation may not be a major contributor in CBZ-SJS/TEN development but, rather,
that interaction among the parent drug (or metabolite(s)), TCR and MHC (Probably class
I, HLA-B*1502) are the main components that initiate the immune response that
manifests in CBZ-SJS/TEN. In line with the p-i hypothesis this scenario is quite possible
and may explain why certain HLA alleles are associated with specific immune
responses.51 Such an effect would be independent of drug bioactivation and hapten
formation and processing, which could explain why the in vitro toxicity assays were
negative in the Han-Chinese child case we presented here.
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7.1. Introduction
Drug hypersensitivity reactions (DHRs) are uncommon but potentially fatal adverse
events. Their diagnosis and prediction is difficult due to variable presentation and
overlap of symptoms with other clinical conditions. Systemic rechallenge is
considered as a gold standard for the diagnosis of DHRs; however, this may have
severe consequences. In vitro tests are currently not sufficiently reliable to provide
the basis for clinical decisions. This article summarises the challenges facing in vitro
testing for DHRs.
Adverse drug reactions (ADRs) account for 6.5% of all hospital admissions and
occur in 10-20% of hospitalized patients.(1, 2) Most ADRs (85-90%) are predictable,
dose-dependent and related to the pharmacology of the drug (Augmented or Type A
reactions), but 10-15% are unpredictable, unrelated to the known pharmacology of the
drug and do not have a clear dose dependency (Bizarre or Type B reactions).(3) Drug
hypersensitivity reactions (DHRs) or drug hypersensitivity syndrome (DHS) are a major
sub-type of Type B reaction. The terms „Type B ADRs‟, „idiosyncratic drug reactions‟
and „drug hypersensitivity‟ have been used to describe the same disease. DHS is a rare
but potentially fatal disorder that occurs in susceptible patients following exposure to
specific drugs. Classes of drugs most associated with DHS include β-lactam antibiotics,
sulfonamides, dapsone, minocycline, terbinafine, azathioprine, allopurinol, NSAIDs and
aromatic antiepileptics. DHRs include all immune-mediated drug hypersensitivity
reactions ( Types I to IV) while DHS refers more specifically to specific reactions
characterized by delayed-onset constellation of symptoms including fever, rash and
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multiple organ involvement. It has not been possible to accurately define the true
incidence of DHRs due to difficulty in identification and classification as well as
relatively few comprehensive studies, but it has been estimated to represent one sixth of
all ADRs.(4)
Our incomplete understanding of the etiology and pathophysiology of DHRs has
made it difficult to come to agreement on their classification and nomenclature. However,
a general classification of „allergic reactions‟ has been adopted to describe DHRs (Table
1).(5) The Gell and Coombs classification for immune-mediated reactions does not
provide a mechanistically comprehensive classification system for DHR but it is a
clinically relevant system that classifies DHRs into immediate, accelerated and delayed
reactions related to the temporal relationship between introduction of the causative agent
and appearance of the symptoms (Table 1). (6)
The clinical presentations and presumably the pathophysiology of DHRs are
diverse and complex which make selection of an in vitro approach for their diagnosis or
prediction a challenging task. Available in vitro tests are based either on detecting
activation of the immune system (e.g., measuring immunoglobulins or immune cell
activation) or detecting an enhanced ratio of metabolic activation to detoxication, an
imbalance in drug metabolism (e.g., measuring cell susceptibility to in vitro chemical
insult in metabolically-competent systems, Figure 1). The first category includes tests
that measure drug specific IgE such as RAST (radioallergosorbent test), activation of
basophils (BAT) or T-lymphocytes (e.g., the lymphocyte transformation test, LTT). The
latter category includes the lymphocyte toxicity assay (LTA) as well as the recently
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Table (1): Classification of immune-mediated hypersensitivity reactions (A) and classes
of drugs most associated with causing delayed-type DHRs (B).
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A): Classification of immune-mediated hypersensitivity reactions

Type

mediator

Pathogenesis

Clinical picture

Chronology

I

IgE

Degranulation of Mast
cells and basophils

Urticaria; Anaphylaxis;
Allergic rhinitis;
Bronchospasm;
Angiooedema;

Immediate

Blood Cell Dyscasia

Intermediate

II

IgG/M

FcR dependent cell lysis

(≤ 1 hr)

(5-14 days)
III

IgG/M

FcR-dependent immune
complexes deposition

Serum Sickness;
Vasculitis

Intermediate
(7-8 days)

Arthus reaction
TH1 (IFNγ,
TNFα)

IVa

IVb

TH2-IL4, IL5,
IL13)

Monocyte/macrophage
mediated inflammatory
response

Eczema

Eosinophils mediated
inflammatory response

Maculopapular
exanthema

Delayed
(1-3 weeks)
Delayed
(2-7 weeks)

Bullous exanthema
IVc

IVd

Cytotoxic T
cells
(Perforine,
Granzym B,
FasL)

Cytotoxicity/Apoptosis

T cells (IL8,
CXCL8, GMCSF)

Neutrophils mediated
inflammatory response

Maculopapular
exanthema

Delayed
(1-3 weeks)

Bullous/pustular
exanthema
AGEP

Intermediate

Behςet’s disease

(≤ 2 days)

B): Drugs and classes of drugs most associated with delayed-type DHRs.






β-lactam antibiotics
Sulfonamides
Aromatic antiepileptics
Dapsone
Minocycline







Terbinafine
Azathoprine
Allopurinol
NSAIDs
Quinolones





Abacavir
Nevirapine
Iodinated contrast
media

AGEP, acute generalized exanthematous pustulosis; FcR, Fc receptor; DHRs, drug hypersensitivity
reactions. Adopted from Pichler et al., 2010 (23); Coombs and Gell, 1975 (5); Levine and Ovary, 1961 (6)
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described in vitro platelet toxicity assay (iPTA).(7) This article focuses on the current
status of the in vitro diagnosis of immune-mediated DHRs by describing these tests their
strengths and weaknesses, as well as possible future directions of this quickly evolving
field.
7.2. Challenges in the evaluation of DHS
Factors that contribute to the difficulty of diagnosis of DHS include variable
clinical picture, overlap with other clinical conditions (e.g., infection or malignancy) and
the typical delayed temporal relationship between administration of the causative drug
and the appearance of symptoms.(8) An active debate on whether this constellation of
symptoms represent different degrees of severity of the same disease or distinct
pathological entities is ongoing.(9, 10) Systemic re-challenge is not ethically acceptable
because of the possibility of severe adverse effects to the patient.

Currently, the

diagnosis of DHS is based on the expertise of the treating physician and a comprehensive
clinical work-up of individual cases. This includes detailed clinical and medical histories
and thorough physical examination with laboratory data such as evaluation of liver
function and blood counts as needed.
Developing an in vitro system for the evaluation of DHS would be of great
advantage to researchers, drug regulators and clinicians.

To appreciate potential

approaches, it is important to first consider briefly the putative pathogenesis of DHS.
Briefly put, immediate onset reactions typically are mediated by an antibody such as IgE.
Delayed onset DHS appears to evolve as a result of the complex interplay of a number of
variables (Table 1). This appears to begin with bioactivation, given that a common
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characteristic of drugs causing DHS is the capacity to undergo metabolism to a reactive
intermediate. While there are two competing theories as to the evolution of DHS, the
most widely held hypothesis is that reactive drug intermediates alter the cellular
environment and react with cellular macromolecules, following which these altered
macromolecules are processed by the immune system. The immune response generated
then determines the clinical expression of drug exposure – immune-tolerance or DHS.
Thus, in vitro approaches to the evaluation of DHS would ideally evaluate key steps in
the putative pathogenesis (Figure 1).
7.3. In vitro approaches to drug hypersensitivity reactions.
In vitro testing has the advantage of being safe. Selection of an in vitro diagnostic
test for DHS depends on the type of reactions and the underlying pathophysiology
predicted from the clinical picture and the natural history of the reaction. There are in
vitro tests best used for immediate IgE-mediated reactions and those that are better for
non-immediate or delayed reactions.
7.3.1. In vitro tests for immediate drug hypersensitivity reactions (DHRs).
In vitro tests for immediate hypersensitivity are based primarily on determination
of specific IgE antibodies believed to be key mediators of Type I reactions. RAST,
cellular fluorescent assay-IgE (CAP-IgE) and enzyme-linked immunosorbent assay
(ELISA) are commonly used technologies which are known to have high positive
predictive value (PPV) and low negative predictive value (NPV).(11) Thus, positive
results strongly indicate immune mediation of the reaction but negative results do not
exclude this possibility. Thus, either skin tests or rechallenge is required to determine
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Figure (1): Pathogenesis and in vitro tests used for the diagnosis and prediction of
immune-mediated DHRs (see text for details). A, activation; APC, antigen presenting
cells; BAT, Basophil Activation Test; D, detoxication; iPTA, in vitro Platelet Toxicity
Assay; LTA, Lymphocyte Toxicity Assay; LTT, Lymphocyte Transformation Test;
TCR, T cell receptor.
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safety of future therapy. As an example, one commercially available test (CAP-FEIA,
Phadia®) was found to have sensitivity between 0 and 25% and specificity ranging from
83.3% to 100%, respectively, in diagnosis of immediate reactions to β-lactam antibiotics
and the variation was reported to be dependent on the clinical manifestations.(12)
Measurement of drug specific IgE antibodies is widely used for diagnosis of immediate
reactions to β-lactam antibiotics, muscle relaxants and some NSAIDs.
Another cellular in vitro test for immediate hypersensitivity is the basophil
activation test (BAT). Basophils respond to antigen stimulation in vitro by degranulation
(e.g., release of histamine and leukotrienes) and expression of certain surface markers
(e.g., CD45, CD11b, CD11c, CD62L, CD203c and CD63). Release of mediators
including histamine can be measured in the media as an indicator of basophil activation
although this method is limited by low sensitivity. Sensitivity was increased by the use of
fluorescent antibodies for these surface markers coupled to flow cytometry. This latter
test has been useful as an allergenic diagnostic approach and has been

validated

clinically for Type I reactions to muscle relaxants(13), β-lactam antibiotics(14),
pyrazolones and certain NSAIDs(15, 16). The disadvantages of BAT include its
relatively low sensitivity and its availability for only a limited number of drugs (Table
2).(17)
The lymphocyte transformation test (LTT) is a cellular test based on measurement
of drug-specific T cells in samples of peripheral blood from patients with a suspected
DHR. Although this test is mainly used for assessment of delayed T cell-mediated
reactions (see below) positive LTT results also occur with type I (IgE-mediated)
172

reactions.(18) Although this may appear contradictory, it must be recalled that the
production of drug-specific antibodies requires activation of T cells.
7.3.2. In vitro tests for non-immediate (delayed) hypersensitivity reactions
Delayed, presumably T-cell-mediated, DHRs are believed to be a result of a
complex interplay of many different factors and pathways. Biochemical and genetic
approaches have recently begun to shed some light on the pathophysiology of these types
of devastating and potentially lethal ADRs. Understanding this pathophysiology is a
prerequisite for development of evidence-based and biologically grounded approaches to
manage this disease. Although some exceptions do exist, metabolic activation of drugs to
metabolites normally represent the first step in the cascade of events leading to
development of DHR(19) The „reactive metabolite hypothesis‟ posits that DHR develops
as a result of imbalance between metabolic activation or toxication and detoxication of
drugs in the biological system leading to accumulation of one or more toxic reactive
metabolites.(20, 21) DHS is always associated with either drugs known to be
electrophilic or those readily bioactivated to electrophilic metabolites capable of
covalently modifying endogenous macromolecules, including proteins and DNA.(22) It is
important to understand that „reactive metabolites‟ may not be the principle direct
activator of the immune system as parent, non-reactive drugs can activate isolated T-cells
in vitro without need for any bioactivation.(23) However, chemically reactive
electrophilic metabolites seem to be the major, if perhaps not the only, products capable
of

supporting two important pathways in the immune system activation process:

generation of haptenated endogenous proteins (act as antigens, signal 1) and generation
of danger signals from stressed and dying cells (signal 2, Figure 1).(9) Signal 2 can also
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be provided by factors such as trauma, bacterial and viral infections, or co-administered
drugs and environmental pollutants. The clinical manifestations of DHS are probably
primarily mediated by the immune system although in some cases a direct toxic effect of
the reactive species generated from the drug during metabolism may be manifested
clinically.(24) As an example, the immune response may be responsible for the skin
reaction whereas enhanced formation of cytotoxic metabolites may result in liver or
kidney dysfunction. It has been established for several decades that cells from DHS
patients (peripheral blood mononuclear cells, PBMCs) are more susceptible to in vitro
toxicity from the reactive metabolite(s) of the suspected drug than are cells from healthy
individuals (controls) who have tolerated the drug.(25) These observations prompted the
development of the lymphocyte toxicity assay (LTA).(26)
7.3.3. The lymphocyte toxicity assay (LTA)
The LTA is performed by isolation of PBMCs (lymphocytes) from blood samples
withdrawn from patients and incubation of these cells with the suspected drug metabolite
(if known and available) or the parent drug in the presence of a metabolic activation
system (usually Phenobarbital-induced rat liver microsomes, RLM).(27) Following
incubation with different concentrations of the tested drug for 2 h at 37°C, cells are
allowed to recover for 16 hr and viability is then determined using different methods
(e.g., trypan blue exclusion, MTT). Degrees of cell death are then expressed as
percentage of the control and compared with percentage of cell death in cells from
healthy individuals who do not experience an ADR with the same drug (controls). A preselected increase in the percentage of cell death of incubated patient cells (vs controls) is
considered as an indication of patient susceptibility.(28) The predictive value of this test
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remains difficult to define due to lack of a „gold standard‟ test for comparison, and the
technical complexity of the test.
We have recently performed a population survey on a cohort of pre-tested patients
to evaluate the predictive values of the LTA for diagnosis of DHS.(29) In this study we
included 147 patients who developed a DHS to primarily 3 different classes of drugs, βlactam antibiotics, sulphonamides or aromatic anticonvulsants. It is clear from our
evaluation that the performance of the LTA test is different in cases involving each one
of these drug classes.(29)
The most complicated and non-standardized step in the test is the metabolic
activation system using RLM. In some cases a murine system will not generate the same
metabolite(s) of a particular drug at the same concentration(s) as would be generated in
humans in vivo over the course of therapy. There are many pharmacokinetic and
pharmacodynamic factors in humans that are unaccounted for in the in vitro activation
systems, including lack of several functional detoxication pathways. This is supported by
the observation that use of the synthetic reactive metabolite (as in case of sulfonamide
drugs) resulted in increased test sensitivity and a positive predictive value of 100% (29).
Another factor limiting the more routine use of the LTA is the requirement for careful
isolation of white blood cells. Therefore, we have explored the possibility of using blood
platelets as an alternate cell model for in vitro toxicity testing.(27)
7.3.4. The in vitro platelet toxicity assay (iPTA)
In order to overcome many of the limitations of the LTA test and to simplify the
procedure to encourage wider clinical use, recent research in our lab focused on
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development and validation of peripheral blood platelets (thrombocytes) as a surrogate
cell model for in vitro toxicity testing.(7) Thrombocytes are metabolically active nonnucleated cells of 2.0 to 5.0 µm in diameter, 0.5 µm in thickness and abundance of 150450×109 cells/L.(30) Due to their small size and low density, they are readily collected
from peripheral blood using differential centrifugation.(31) In addition to blood
homeostasis, their role in inflammation, allergy and hypersensitivity reactions has
recently been recognized.(32-35) Thrombocytes have active mitochondria and complete
apoptotic system, suggesting they can serve as a cellular model for studying drug
toxicity. Furthermore, they do not proliferate which is an advantage in studying the
degree of cell death. We have found that platelets from hypersensitive patients respond to
in vitro chemical insult in a similar fashion to PBMCs; however, the degree of cell death
is greater and easier to detect.(7) We speculate that platelets have lower capacity for
detoxication of reactive metabolites.
Validation of any novel diagnostic test requires the availability of a „gold
standard‟ for comparison. Unfortunately, this is lacking in DHS because systemic
rechallege data are generally unavailable. To validate the novel iPTA we used two
approaches: (i) inclusion of rigorously identified DHS cases known to be caused by
treatment with sulphonamide drugs (sulfa-DHS); and (ii) the use of the LTA, which we
showed to have a positive predictive value of 100% in cases of DHS due to sulfa drugs in
patients that had been clinically re-exposed.(29) Using a 20% increase in cell death as a
cut-off value, there was 85% agreement (11 out of 13) between the LTA and the iPTA
results in the 13 sulfa-DHS cases we tested.(36) In the two cases where the two tests did
not agree the LTA was negative and the iPTA was positive, and of importance, these two
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cases were clinically confirmed as sulfa-DHS cases. We think that this disagreement
between the LTA and the iPTA results from the higher sensitivity of the platelet test to
detect patient susceptibility.
The iPTA offers a simplified procedure for in vitro toxicity testing for DHS with
higher sensitivity than the LTA. We believe that the iPTA is more suitable as a diagnostic
procedure for DHS for wider clinical use than the LTA.
7.3.5. The lymphocyte transformation test (LTT)
A frequent feature of DHS is the presence of drug specific T-cell clones in the
circulation of affected patients. These drug specific T-cell clones can be isolated and
cloned in vitro; typically, they respond to incubation with the culprit drug with
proliferation and expression of certain surface markers. Cell proliferation and surface
markers can be measured using different methods and have been used as a measure of
specific immune system response to the drug. This technique also involves isolation of
PBMCs using differential gradient centrifugation and is prone to the same technical
complexity as the LTA, a limitation that confines its use to well equipped research labs
rather than labs designed for clinical diagnosis.(37) For a detailed description of this test
procedure and its history please refer to Elzagallaai et al., 2009.(27)

The LTT has been useful in defining clonal responses to drugs implicated in DHS.
While these clones have been helpful in studying the immune response to drugs and drug
metabolites, the LTT suffers from the same difficulty in extrapolating in vitro responses
to in vivo clinical conditions as does the LTA.
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Table (2): Advantages and disadvantages of in vitro tests used for diagnosis and
prediction of DHRs.
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The sensitivity of the LTT for the diagnosis of DHS has been estimated to be from 56%
to 78% and its specificity to range from 85% to 93%.(27) There are many factors that
were found to affect the predictive ability of the LTT which include: (i) timing of the test
in respect to the initial reaction; (ii) the clinical picture of the reactions; (iii) the type of
drug involved; and (iv) the test procedure and read-out systems used.
7.4. Conclusion and future directions
Evaluation and management of immune-mediated DHRs require a great deal of
clinical and laboratory experience and expertise.(38, 39) Advantages and disadvantages
of the currently used in vitro tests for DHRs are summarized in table (2). We believe that
the major current challenge for better in vitro approaches is incomplete understanding of
the underlying pathophysiology of these complex ADRs. Genetic testing for predisposing
alleles for DHRs has recently increased exponentially as the methodology to study the
genome becomes more sophisticated while simultaneously per-test cost has declined.
Genetic analysis has linked a few specific ADRs with certain polymorphisms for certain
drugs in specific ethnic groups (e.g., HLA B*-1502 for carbamazepine-induced severe
bullous

reactions

in

the

Han

Chinese

and

HLA

B*-5701

and

abacavir

hypersensitivity)(40). However, these studies have also made it clear that much more
work is required in both basic and clinical science to enable us to better predict, manage
and prevent this type of ADRs.

Further research is required to elucidate the

pathophysiology of DHS as well as rigorous trials to determine which of the available in
vitro evaluations is most suitable for the assessment of patients or research subjects with
possible DHRs.
180

Conflict of interest/Disclosure
The authors declare no conflict of interest directly related to the contents of this
manuscript.

181

References
1.

Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M.
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695
patient-episodes. PLoS ONE2009;4(2):e4439.

2.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse
drug reactions as cause of admission to hospital: prospective analysis of 18 820
patients. BMJ2004 Jul 3;329(7456):15-9.

3.

Rawlins M, Thompson J. Mechanisms of adverse drug reactions. In: Davies D,
editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1991.
p. 18-45.

4.

Pichler W. Drug hypersensitivity reactions: Classification and relationship to T-cell
activation. In: Pichler W, editor. Drug hypersensitivity. Basel: Karger; 2007. p.
168-89.

5.

Coombs R, Gell P. Classification of allergic reactions responsible for clinical
hypersensitivity and disease. In: Gell P, Coombs R, Lachmann P, editors. Clinical
aspects of immunology. London: Blackwell Scientific publications; 1975. p. 76181.

6.

Levine BB, Ovary Z. Studies on the mechanism of the formation of the penicillin
antigen. III. The N-(D-alpha-benzylpenicilloyl) group as an antigenic determinant
responsible for hypersensitivity to penicillin G. J Exp Med1961 Dec 1;114:875904.

7.

Elzagallaai AA, Rieder MJ, Koren G. The In Vitro Platelet Toxicity Assay (iPTA):
A Novel Approach for Assessment of Drug Hypersensitivity Syndrome. J Clin
Pharmacol2010 Apr 16.

8.

Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch
testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic
review. Drug Saf2009;32(5):391-408.

9.

Elzagallaai A, Garcia-Bournissen F, Finkelstein Y, Bend G, Rieder M, Koren G.
Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han
Chinese child with a positive HLA-B*1502 and negative in vitro toxicity assays:
Evidence for different pathophysiological mechanisms. J Popul Ther Clin
Pharmacol, 2011;In press.

10. Peyriere H, Dereure O, Breton H, Demoly P, Cociglio M, Blayac JP, et al.
Variability in the clinical pattern of cutaneous side-effects of drugs with systemic
symptoms: does a DRESS syndrome really exist? Br J Dermatol2006
Aug;155(2):422-8.
182

11. Edwards RG, Spackman DA, Dewdney JM. Development and use of three new
radioallergosorbent tests in the diagnosis of penicillin allergy. Int Arch Allergy
Appl Immunol1982;68(4):352-7.
12. Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M, et al.
Relevance of the determination of serum-specific IgE antibodies in the diagnosis of
immediate beta-lactam allergy. Allergy2007 Jan;62(1):47-52.
13. Abuaf N, Rajoely B, Ghazouani E, Levy DA, Pecquet C, Chabane H, et al.
Validation of a flow cytometric assay detecting in vitro basophil activation for the
diagnosis of muscle relaxant allergy. J Allergy Clin Immunol1999 Aug;104(2 Pt
1):411-8.
14. Torres MJ, Padial A, Mayorga C, Fernandez T, Sanchez-Sabate E, Cornejo-Garcia
JA, et al. The diagnostic interpretation of basophil activation test in immediate
allergic reactions to betalactams. Clin Exp Allergy2004 Nov;34(11):1768-75.
15. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric
basophil activation and determination of sulfidoleukotrienes is useful for in vitro
diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory
drugs. Int Arch Allergy Immunol2005 Jan;136(1):58-72.
16. De Weck AL, Sanz ML, Gamboa PM, Aberer W, Blanca M, Correia S, et al.
Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter
study. I. Clinical findings and in vitro diagnosis. J Investig Allergol Clin
Immunol2009;19(5):355-69.
17. Mayorga C, Sanz ML, Gamboa PM, Garcia BE, Caballero MT, Garcia JM, et al. In
vitro diagnosis of immediate allergic reactions to drugs: an update. J Investig
Allergol Clin Immunol;20(2):103-9.
18. Bircher AJ. Lymphocyte transformation test in the diagnosis of immediate type
hypersensitivity reactions to penicillins. Curr Probl Dermatol1995;22:31-7.
19. Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK. Reactive
metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol2001
Aug;1(4):317-25.
20. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive
metabolite syndromes. Lancet2000 Nov 4;356(9241):1587-91.
21. Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin
Cutan Med Surg1996 Dec;15(4):217-27.
22. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev
Pharmacol Toxicol2007;47:513-39.
183

23. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D. Drug
hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin
North Am Jul;94(4):645-64, xv.
24. Horton JK, Rosenior JC, Bend JR, Anderson MW. Quantitation of benzo(a)pyrene
metabolite: DNA adducts in selected hepatic and pulmonary cell types isolated
from [3H]benzo(a)pyrene-treated rabbits. Cancer Res1985 Aug;45(8):3477-81.
25. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro
assessment of risk. J Clin Invest1988 Dec;82(6):1826-32.
26. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to
phenytoin hepatotoxicity assessed in vitro. N Engl J Med1981 Sep 24;305(13):7227.
27. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. In vitro
testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic
review. Mol Diagn Ther2009;13(5):313-30.
28. Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to
assess drug hypersensitivity syndromes. Clin Biochem2000 Oct;33(7):517-24.
29. Elzagallaai AA, Jahedmotlagh Z, Del Pozzo-Magana BR, Knowles SR, Prasad AN,
Shear NH, et al. Predictive value of the lymphocyte toxicity assay in the diagnosis
of drug hypersensitivity syndrome. Mol Diagn Ther2010 Oct 1;14(5):317-22.
30. White J. Platelet structure. In: Michelson A, editor. Platelets. Burlington, MA,
USA: Academic Press; 2007. p. 45-74.
31. McNicol A. Platelet preparation and estimation of functional responses. In: Watson
S, Authi K, editors. Platelets. Oxford, UK: Oxford University Press; 1996. p. 1-26.
32. Capron A, Joseph M, Ameisen JC, Capron M, Pancre V, Auriault C. Platelets as
effectors in immune and hypersensitivity reactions. Int Arch Allergy Appl
Immunol1987;82(3-4):307-12.
33. Pitchford SC. Defining a role for platelets in allergic inflammation. Biochem Soc
Trans2007 Nov;35(Pt 5):1104-8.
34. Pitchford SC, Yano H, Lever R, Riffo-Vasquez Y, Ciferri S, Rose MJ, et al.
Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy
Clin Immunol2003 Jul;112(1):109-18.
35. Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelets play important roles in the
late phase of the immediate hypersensitivity reaction. J Allergy Clin Immunol2009
Mar;123(3):581-7, 7 e1-9.

184

36. Elzagallaai A, Rieder M, Koren G. The in vitro platelet toxicity assay (iPTA):
validation of the novel diagnostic test for drug hypersensitivity syndrome. Annual
meeting of the American Society for Clinical Pharmacology and Therapeutics; 2-5
March, 2011; Dallas, TX, USA2011.
37. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al.
Hypersensitivity reactions to carbamazepine: characterization of the specificity,
phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol2003
Mar;63(3):732-41.
38. Birchler A. Approach to the patient with a drug hypersensitivity reactions-clinical
perspectives. In: Pichler W, editor. Drug hypersensitivity. Basel: Karger; 2007. p.
352-65.
39. Schnyder B. Approach to the patient with drug allergy. Med Clin North Am
Jul;94(4):665-79, xv.
40. Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. Handb
Exp Pharmacol(196):477-91.

185

Appendices
Appendix 1: Copyright approval for previously published work.
1.1. Copyright policies of Adis published of Drug Safety and Molecular Diagnosis and
Therapy.

186

1.3.

Permission for re-publishing from the journal of population therapeutic and
clinical
pharmacology.

187

1.3. Copyright policyies of SAGE, published of the Journal of Clinical Pharmacology

188

Appendix 2. Patient questionnaire form.

189

190

Appendix 3. Research Ethics Board (REB) approval.

191

Curriculum Vitae
Name:

Abdelbaset A Elzagallaai

Qualifications:
BSc. Pharmacy (1991) Faculty of Pharmacy, Al-Fateh University, Triploi, Libya
MSc. Pharmacology, (2000) Department of cellular and Molecular medicine, Faculty of
Medicine, University of Ottawa, Ottawa, Ontario, Canada. Thesis title “Presence of
Myristoylated Alanine Rich C Kinase Substrate (MARCKS) in Platelets and its Role in
Secretion”
Work Experience and Academic positions:
1993-1995:

Demonstrator (teaching assistant), Department of Toxicology, Faculty of
Pharmacy, Garyounis University, Benghazi, Libya.

1996-2000:

MSc Graduate student, Department of cellular and Molecular Medicine,
Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

2000-2004:

Assistant lecturer and Chairman, Department of Toxicology, Faculty of
Pharmacy, Garyounis University, Benghazi, Libya.

2004-2006:

Lecturer and Chairman, Department of Toxicology, Faculty of Pharmacy,
Garyounis University, Benghazi, Libya.

2001-2006

Director, Faculty of Pharmacy researches centre, Faculty of Pharmacy,
Garyounis University, Benghazi, Libya.

2007-present PhD graduate student and teaching assistant, Department of Physiology
and Pharmacology, Schulich School of Medicine and Dentistry, The
University of Western Ontario, London, Ontario, Canada.
Technical training:
Advance workshop on atomic absorption spectroscopy, Analytikjena Group, June 21st 27th, 2004, Jena, Germany.
Training on the operation of nuclear magnetic resonance (NMR) spectroscope,
September 12th -15th, 2004, Benghazi, Libya. Organized by Bruker Biospin, France.
The 3rd Hong Kong University (HKU)-Pasteur Immunology Course, October 31st –
November 12th, 2010. Hong Kong, China.
192

Awards:
The Libyan Ministry of Higher Education MSc Scholarship award (1995-2000).
The Libyan Ministry of Higher Education PhD Scholarship award (2006-Present).
American Society for Clinical Pharmacology and Therapeutics ASCPT Presidential Trainee
Award, 2011.
Publications:
1. Elzagallaai

AA, Rieder MJ and Koren G. The In vitro Platelet Toxicity Assay (iPTA):
validation of the novel diagnostic test for drug hypersensitivity syndrome. Under
preparation.

2. Elzagallaai

AA, Koren G, Bend JR and Rieder MJ. Challenges and Future Directions for In
Vitro Testing for Hypersensitivity Mediated Adverse Drug Reactions. J Clin Pharmacol &
Therap. In press.

3. Elzagallaai

AA, Garcia-Bournissen F, Finkelstein Y, Rieder MJ and Koren G. Severe
bullous hypersensitivity reactions after exposure to carbamazepine in Han Chinese child
with positive HLA-B*1502 and negative lymphocyte toxicity assay: A window to different
pathophysiological mechanisms. J Pop Ther Clin Pharmacol. 2011;18(1):e1-9.

4. Elzagallaai

AA, Rieder MJ and Koren G. The In vitro Platelet Toxicity Assay (iPTA) - a
Novel Approach for Assessment of Drug Hypersensitivity Syndrome. J Clin. Pharm, 2010
Apr 16.

5. ELzagallaai AA, Jahedmotlagh Z, Del Pozzo-Magañ BR, Knowles SR, Prasad AN, Shear NH,

Rieder MJ, and Koren G. Predictive Value of the Lymphocyte Toxicity Assay in Diagnosis
of Drug Hypersensitivity Syndrome, Mol Diagn Ther, 2010 Oct 1;14(5):317-22.
6. Elzagallaai

AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. in vitro testing for
the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol
Diagn Ther. 2009;13(5):313-30.

7. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. Patch testing for the

diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf.
2009;32(5):391-408
8. Elzagallaai

AA, Rose SD, Brandan NC, Trifaro JM. Myristoylated alanine-rich C kinase
substrate phosphorylation is involved in thrombin-induced serotonin release from
platelets. Br J Haematol. 2001;112(3):593-602.

9. Lejen

T, Skolnik K, Rose SD, Marcu MG, Elzagallaai AA, Trifaro JM. An antisense
oligodeoxynucleotide targeted to chromaffin cell scinderin gene decreased scinderin
levels and inhibited depolarization-induced cortical F-actin disassembly and exocytosis. J
Neurochem. 2001;76(3):768-77.
193

Trifaro J, Rose SD, Lejen T, Elzagallaai AA. Two pathways control chromaffin cell
cortical F-actin dynamics during exocytosis. Biochimie. 2000;82(4):339-52.

10.

Elzagallaai AA, Rose SD, Trifaro JM. Platelet secretion induced by phorbol esters
stimulation is mediated through phosphorylation of MARCKS: a MARCKS-derived
peptide blocks MARCKS phosphorylation and serotonin release without affecting
pleckstrin phosphorylation. Blood. 2000; 95(3):894-902.

11.

Marcu MG, Zhang L, Elzagallaai AA, Trifaro JM. Localization by segmental deletion
analysis and functional characterization of a third actin-binding site in domain 5 of
scinderin. J Biol Chem. 1998; 273(6):3661-8.

12.

Invited Speaker:
Drug Information Association (DIA) workshop: Personalized Medicine: Biomarkers and
Diagnostics in Drug Development, Regulatory Approval, and Access to Patients: October
15-16, 2009, Toronto, ON, Canada.
American Society for Clnical Pharmacalology and Therapeutic (ASCPT) annual meeting,
Drug Safety, Vaccines: Challenges and potentials. March 2-5, 2011, Dallas, TX, USA..
Peer-reviewing activity:
Reviewer for the Journal of Therapeutic Drug Monitoring
Reviewer for the Journal of Clinical Pharmacology
Affiliations:
Member of the Libyan Pharmaceutical Society (LPS)
Member of the Libyan Society of Biological Technology (LSBT)
Member of the Canadian Society of Pharmacology and Therapeutics (CSPT)
Member of the Canadian Pharmacists Association (CPhA)
Member of the American Society for Clinical Pharmacology and Therapeutics (ASCPT)
Member of the European Academy of Allergy and Clinical Immunology (EAACI)

194

